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CHAPTER I 
 
 
INTRODUCTION 
 The prevalence of obesity in the United States is estimated to be 30% across the 
population and continues to rise 
[1,2]
. Obesity is characterized as a body mass index (BMI) 
exceeding 30 kg/m
2
. Obesity is considered to be a significant risk factor for many chronic 
and life threatening diseases such as hypertension, cancer, cardiovascular disease and 
type 2 diabetes mellitus. Obesity, which may be associated with consumption of a high 
fat diet, contributes to the development of insulin resistance, the primary cause of type 2 
diabetes 
[3]
. The incidence of type 2 diabetes has also increased as a high fat diet has 
become widely consumed 
[3]
.       ` 
 Obesity is also associated with a chronic low-grade inflammation, a condition 
thought to be a primary factor in the development of insulin resistance in obese 
individuals. Inflammatory pathways are activated due to the presence of harmful stimuli 
in the body, with the ultimate goal of returning the body to a normal physiological state 
[4]
. The classic inflammatory pathway leads to an increase in the secretion and circulation 
of pro-inflammatory cytokines, secretion of acute phase proteins, and the activation of 
inflammatory responses to repair maintain homeostasis 
[4]
.  
The chronic low-grade inflammation associated with obesity involves an 
increased circulation of pro-inflammatory cytokines as well as a decrease in protective 
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proteins and hormones, such as adiponectin. The chronic nature of obesity-induced 
inflammation causes dysfunction and deregulation of metabolic functions that maintain 
glucose homeostasis. Inflammation leads to insulin resistance through the secretion of 
inflammatory cytokines, adipose tissue dysfunction, and the activation of inflammatory 
pathways through protein receptors such as the toll like receptor (TLR) 4 
[4,5]
.  
Insulin resistance is defined as the inability of cells to respond to circulating 
insulin. Insulin resistance inhibits the insulin signaling cascade and prevents the entry of 
glucose into cells. Insulin exerts its main effects on cells within the adipose tissue, muscle 
and liver. It is responsible for regulating glucose entry into these cells and is also needed 
for the regulation of plasma free fatty acid (FFA) concentrations by inhibiting lipolysis 
[6]
.  The action of insulin is inhibited in obese individuals due to increases in pro-
inflammatory cytokines, which inhibit insulin signaling by acting on the insulin receptor 
substrate (IRS) 1. This interruption in insulin signaling leads to insulin resistance, altering 
glucose homeostasis and causing an increase in plasma FFA concentrations.  
 TLR 4 is a protein receptor located on the cell membrane of most cells in the 
body, with the expression of this receptor on adipocytes and immune cells such as 
monocytes and macrophages being especially high 
[5,7]
.  Activation of TLR 4 is a result of 
ligand binding by free fatty acids, lipopolysaccharides (LPS) and endogenous proteins. 
These ligands, particularly free fatty acids, are increased in obese individuals due to the 
expansion of adipocytes and are often elevated in association with the consumption of a 
high fat diet 
[7]
.  
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 The activation of TLR 4 leads to stimulation of the innate immune system, the 
body’s first line defense in response to pathogens, and subsequent inflammatory 
processes, inhibition of insulin signaling, and stimulation of pro-inflammatory cytokine 
production. Together, these effects impair insulin function and signaling. TLR 4 deficient 
mice have been shown to exhibit alterations in body composition and reduced activation 
of inflammatory pathways, which lead to improved insulin sensitivity
 [3,5]
. However, it is 
important to note that TLR 4 is not the only mechanism through which a high fat diet 
contributes to insulin resistance.  For example, a high fat diet has been shown to elevate 
the production of pro-inflammatory cytokines from the white adipose tissue which can 
induce insulin resistance independent of TLR 4 
[4,5]
.  
 Dietary approaches to improve the inflammatory state associated with obesity are 
also an important approach on which much research is focused. Dietary measures such as 
the consumption of specific fruits and vegetables or the phytochemicals from these foods 
have been shown to aid in reduction of inflammation and insulin resistance 
[8, 9, 10]
. While 
the mechanism(s) responsible for these effects remains uncertain, dietary phytochemicals 
have been linked to a reduction in adipose tissue mass, improvements in glucose 
tolerance, and reduced inflammation 
[11]
.  
A specific food used in this manner is bitter melon (Momordica charantia, MC), 
an Asian fruit that has been demonstrated to have hypoglycemic effects 
[11-14]
. Various 
studies have shown bitter melon’s insulin-like effects due to its ability to increase glucose 
uptake by peripheral tissues 
[12]
. Bitter melon contains the peptides charantin, vicine, and 
polypeptide-p, compounds thought to be responsible for the hypoglycemic effect of bitter 
melon 
[13,14]
. MC also contains significant amounts of vitamins and minerals that give its 
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antioxidant and anti-inflammatory effect 
[11]
. It is hypothesized that because of the 
bioactive components found in MC, the addition of MC in the diet will provide protection 
from obesity-associated inflammation subsequently lessening tissue insulin resistance. 
 The objective of this study is to determine the effect that MC in 1% and 10% 
(w/w) dose in combination with a high fat diet (60% kcal from fat) on clinical parameters 
and body composition in both mice that easily develop obesity and insulin resistance 
(C57Bl/6) and mice with a null mutation in the TLR 4 receptor (C3H/HeJ).  
 Our null hypotheses are that: 
1) Bitter melon added to a high fat diet will not improve the plasma lipid profile in 
both strains of mice.  
2) Bitter melon will not affect glucose homeostasis in both strains of mice.  
3) Biomarkers of inflammation will not be lower in mice fed bitter melon compared 
to mice consuming a high fat diet in both strains of mice. 
4) Bitter melon will not affect body composition in both strains of mice.  
If bitter melon is found to have a positive effect on lipid parameters, body 
composition and glucose homeostasis, it could potentially be used as a dietary option 
to improve these parameters. The findings of this study may also aid in identifying 
the role of TLR 4 in the development of inflammation and insulin resistance. The 
results of this study may also provide an understanding whether inhibition of the 
activation of TLR 4 is one of the mechanisms by which bitter melon exerts positive 
effects on glucose and lipid parameters.
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
Prevalence of Obesity and Type 2 Diabetes Mellitus   
  Obesity prevalence continues to rise and has significantly increased over the last 
decade. As reported by the Center for Disease Control (CDC), the prevalence of obesity 
in the United States is estimated to be over 30% in most age groups and in both genders 
[1]
. Due to the rise in obesity, complications associated with obesity, such as heart disease 
diabetes mellitus, and some cancers have also shown an increase 
[1]
. 
 Research efforts are focused on determining the pathogenesis of obesity-
associated complications 
[4]
.  Of these complications, the development of insulin 
resistance in response to chronic inflammation has been indicated as the direct link 
between obesity and type 2 diabetes mellitus 
[1, 2]
. Parallel to the rise in obesity is an 
increase in the prevalence of type 2 diabetes. Regions in the United States with the 
highest obesity rates also have the highest incidence of type 2 diabetes 
[15]
.  The 
American Diabetes Association estimated that 25.8 million Americans suffer with type 2 
diabetes or complete insulin resistance and that nearly 79 million are prediabetic, 
characterized as a fasting blood glucose between 100 mg/dL and 126 mg/dL 
[16]
. 
Individuals with insulin resistance and diabetes are at an increased risk for hypertension 
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and dyslipidemia, which lead to an increased risk for developing cardiovascular disease 
and other complications 
[17]
.  
Healthcare costs related to diabetes are estimated to be $218 billion in the United 
States annually; however this does not account for the costs associated with 
complications and chronic conditions developed due to type 2 diabetes and obesity 
[18]
. 
High healthcare costs, as well as the complications associated with type 2 diabetes and 
obesity, have left clinicians and patients searching for additional prevention and treatment 
methods.  
Pro-inflammatory State of Obesity 
 Obesity is associated with a chronic low-grade inflammation due to the body’s 
response to harmful stimuli, specifically elevated levels of endogenous free fatty acids 
derived from adipose tissue 
[4].  The body’s response involves activation of the innate 
immune system as well as systemic increases in circulating pro-inflammatory cytokines. 
Tumor necrosis factor (TNF) α, interlukin-6 (IL-6) and C-reactive protein (CRP) are 
especially elevated in obese individuals 
[4,19]
.  
The accumulation of lipids in the adipocytes causes an expansion, via 
hypertrophy, of adipose tissue and leads to an increase in secretions from adipose tissue. 
Adipose tissue secretes adipokines, hormones, and cytokines that act both locally and 
systemically to affect various tissues 
[5]
. The increase in these secretions leads to an 
elevation in the systemic amounts of pro-inflammatory cytokines and adipokines. These 
secretions also act locally on the endothelial cells within the adipose tissue to promote 
macrophage recruitment to the site of inflammation 
[20]
. The increased presence of 
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macrophages within adipose tissue also elevates the inflammation locally and further 
contributes to the inflammation present systemically. Together, these inflammatory 
changes associated with obesity lead to chronic low grade inflammation which has the 
potential to cause complications such as insulin resistance and type 2 diabetes.  
Insulin Resistance 
 Insulin resistance has been considered clinically relevant because of its 
association with several medical conditions; including hypertension, dyslipidemia, non-
alcoholic fatty liver disease, and metabolic syndrome, all contributing to the development 
of cardiovascular disease. Insulin resistance is defined as the inability of insulin-sensitive 
tissues to respond to normal amounts of circulating insulin and affects several metabolic 
pathways including glucose transport, glycogen synthesis and inhibition of lipolysis 
[21]
. 
Tissues such as skeletal muscle, liver and adipose tissue are especially affected by insulin 
resistance 
[19,22]
. Insulin resistance leads to the inability of these tissues to bring glucose 
into the cell to be utilized for energy. The state of insulin resistance is characterized by 
increased plasma free fatty acid concentrations and hyperglycemia, due to the inability 
for insulin to modulate lipolysis, hepatic glucose output and skeletal muscle glucose 
utilization 
[21,22]
.  
Insulin is an anabolic hormone essential for regulating metabolic processes 
throughout the human body. The actions of insulin are carried out through activation of 
intracellular signaling cascades 
[19]
. The binding of insulin to its receptor, the insulin 
receptor (IR), causes the phosphorylation of tyrosine residues present on the insulin 
receptor substrate (IRS). This phosphorylation is important to induce the activation of 
8 
 
kinases such as phosphatidylinositol 3-kinase (PI3K), which in turn causes the activation 
of 3-phosphoinositide-dependent protein kinase (PDK) 1, and further activation of 
Akt/protein kinase B (PKB) 
[19,23]
. PKB targets downstream proteins allowing for the 
translocation of glucose transporter type (GLUT) 4, an insulin sensitive receptor, from 
vesicles within the cytoplasm to the cell membrane to facilitate glucose entry into the 
cell, specifically within adipose tissue and skeletal muscle. Within the liver, insulin 
regulates gluconeogenesis and the production of glycogen to maintain glucose 
homeostasis.   
Interruption at any point along the insulin signaling cascade results in insulin 
resistance. Down regulation of the insulin receptor or the insulin receptor substrate 
protein level is often seen in state of hyperinsulinemia and obesity leading to insulin 
resistance in insulin sensitive cells. Insulin induces the phosphorylation of serine and 
tyrosine on insulin substrates an action requiring fine tuning and a strict balance of serine 
and tyrosine phosphorylation at the appropriate time during insulin signaling 
[24]
. 
Inhibitory sites on the IRS can be phosphorylated in response to stimuli, including free 
fatty acids, pro-inflammatory cytokines and various inflammatory pathways, all of which 
may be elevated in obesity, there by promoting insulin resistance 
[5,19]
. Serine 
phosphorylation, rather than tyrosine, of the IRS is also a major point of alteration along 
the insulin signaling cascade. Serine phosphorylation of IRS prevents further insulin 
signaling from occurring 
[19]
.  
Genetic, lifestyle, and environmental factors play an important role in the 
development of insulin resistance 
[22]
. Risk factors for developing insulin resistance 
include obesity, physical inactivity, and aging 
[22]
. Insulin resistance initially results in 
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increased insulin secretion by the pancreatic β cells. Pancreatic islets increase their cell 
mass and β cells increase insulin secretion in order to compensate for the developing 
resistance 
[25]
. However, sustained inflammation and the presence of oxidative stress 
associated with obesity leads to pancreatic β cell dysfunction [25,26]. Pancreatic β cells are 
especially vulnerable to oxidative stress because of their lack of antioxidant-containing 
enzymes 
[25]
. Increased inflammation, due to elevated levels of pro-inflammatory 
cytokines and chemokines, disrupts the circulation of blood to the β cells and contributes 
to dysfunction. Hyperglycemia, related to over nutrition and the progression of insulin 
resistance may also contribute to apoptosis of the β cells [27].  Because of the mounting 
dysfunction within the pancreas due to the resistant state of obesity, the pancreas is no 
longer able to compensate which leads to dysfunction in glucose homeostasis within the 
periphery and the development of type 2 diabetes 
[24-28]
.  
Obesity-Associated Insulin Resistance 
 There is no known direct cause of insulin resistance in obese individuals; rather, 
there are many compounding factors that contribute to the development of insulin 
resistance in obese individuals. Insulin resistance due to obesity occurs as a result of 
many underlying mechanisms, including increased caloric intake, increased circulating 
free fatty acids (FFA), inflammatory cytokines, tissue inflammation and many others 
[28]
. 
Described below are the most understood mechanisms associated with the development 
of insulin resistance in obese individuals.  
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Free Fatty Acids  
 An increase in endogenous circulating free fatty acid concentration is linked to the 
development of obesity associated insulin resistance. FFA concentrations in obese 
individuals are generally increased due to a decreased level of clearance by the liver, as 
well as an increased release from expanding adipose tissue and a reduced suppression of 
lipolysis by insulin, leading to an elevation in plasma FFA levels 
[21,28]
. FFA are released 
from adipocytes during lipolysis when intracellular triglycerides (TG) are hydrolyzed to 
form FFA and a glycerol, a process that is regulated by peroxisome proliferator-activate 
receptors (PPAR)  and insulin [27,29].  The persistent low-grade chronic inflammation 
present in obese individuals and specifically elevations in TNF-, induces lipolysis and 
contributes to the release of FFA from adipocytes
 [29-32]
. Development of insulin 
resistance contributes to increased concentrations of FFA and is caused in part by 
increased FFA levels, creating a vicious cycle.  
 FFA aid in the mounting inflammation present in obese individuals further 
contributing to the development of obesity-associated insulin resistance. FFA, 
specifically long chain fatty acids, make a significant contribution to the low-grade, 
chronic inflammation present in obesity by acting as a ligand for TLR 4. The activation 
of TLR 4 leads to the downstream activation of the inflammatory pathway nuclear factor 
κ B (NFκB) [5]. Activation of this pro-inflammatory pathway increases the transcription 
of pro-inflammatory genes which increase the expression of pro-inflammatory cytokines, 
contributing to obesity-associated insulin resistance. Boden et al. showed an increased 
expression of monocyte cheomoattractant (MCP) 1, TNF-α, and IL-6 in livers of insulin 
resistant rats when infused with lipids to increase FFA concentrations,  suggesting the 
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regulation of these pro-inflammatory cytokines by FFA through a NFκB dependent 
mechanism 
[21,29]
.  
 FFA also inhibit insulin signaling in skeletal muscle and liver. In the liver, FFA 
impair hepatocyte insulin function which enhances the process of gluconeogenesis and 
TG production and limits glycogen synthesis 
[29, 30]
. When FFA concentrations are high, 
FFA are the preferred fuel source over glucose in the muscle through the Randle cycle 
and their use for fuel results in an elevated blood glucose level 
[29]
. Systemic increases in 
FFA can lead to lipid deposition in the liver and muscle, contributing to whole body 
insulin resistance 
[28, 29]
. FFA also inhibit insulin signaling in the skeletal muscle and liver 
by activating pro-inflammatory pathways which induce serine phosphorylation of IRS-1 
[19, 24]
.  
 Not only does an increased FFA concentration contribute to the development of 
insulin resistance, but the presence of insulin resistance also leads to increased plasma 
FFA levels. Insulin resistance results in a decreased ability of insulin to suppress lipolysis 
in the adipose tissue, resulting in an increased FFA flux. This is especially common in 
individuals with android, or central, obesity as visceral fat has a higher rate of lipolysis 
when compared with subcutaneous fat 
[28, 29, and 32]
. Increases in plasma FFA 
concentrations contribute to the presence of inflammation in obese individuals and 
exacerbate insulin resistance progression through pathways discussed previously.  
Inflammatory Pathways and Insulin Signaling  
 Obesity is associated with a chronic low-grade inflammation that contributes to 
the development of obesity-associated insulin resistance 
[5, 6, 22]
.  Obesity, often driven by 
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the consumption of a high fat diet and nutrient overload, triggers inflammatory pathways, 
which inhibit insulin-receptor signaling
 [33, 34]
. Additionally, in the state of chronic 
inflammation, pro-inflammatory cytokines are elevated which can also disrupt the action 
of insulin and interfere with insulin signaling. The two prominent inflammatory pathways 
that affect insulin signaling include JUN N-terminal kinase (JNK) and NFκB [35]. 
Insulin signaling requires the binding of insulin to the insulin receptor located on 
the plasma membrane of myocytes, adipocytes and hepatocytes.  The binding of insulin 
to the insulin receptors induces signaling cascades and allows for GLUT 4 to translocate 
to the cell membrane to bring glucose into the cell, specifically within myocytes and 
adipocytes 
[6, 22, and 23]
.  IRS-1 signaling can specifically be modified in inflammatory 
states through the phosphorylation of serine residues present on IRS-1. Insulin signaling 
requires tyrosine phosphorylation of IRS-1 in order to activate the insulin receptor. 
Inflammatory cytokines and certain protein kinases cause the phosphorylation of serine 
residues, rather than tyrosine, present on IRS-1 
[6, 22]
. The phosphorylation of serine 
residues induces the degradation of IRS-1 and prevents the binding of insulin to the 
insulin receptor, thus causing inhibition of insulin signaling.  
Obesity is associated the activation of JNK at multiple sites such as the muscle, 
adipose tissue and liver. JNK can be activated by various stress signals including the 
presence of reactive oxygen species (ROS), inflammatory cytokines, free fatty acids and 
pathogens 
[35]
. JNK phosphorylation due to the presence of these stress factors, leads to 
serine phosphorylation of IRS, disrupting insulin signaling.  JNK activity has been shown 
to be elevated in obesity and JNK knockout mice have been shown to be protected from 
developing insulin resistance when fed a high fat diet 
[35]
. In addition to phosphorylating   
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serine residues on the insulin receptor, activation of JNK also promotes elevated 
secretions of pro-inflammatory cytokines, exacerbating the inflammatory response and 
causing further activation of other inflammatory pathways such as NFB.  
The activation of NFB also contributes to the development of insulin resistance, 
especially in obesity. NFκB activation stimulates the transcription of inflammatory 
mediators, including TNF-α and IL-6 [36]. The increase in inflammation caused by 
activation of this pathway inhibits insulin signaling by phosphorylating serine residues on 
IRS-1 and acting directly on the insulin receptor. The NFκB pathway is activated through 
the binding of pro-inflammatory ligands such as TNF- and lipopolysaccharides (LPS) to 
their membrane bound receptors, for example the toll like receptors. This causes the 
phosphorylation of the IB protein, the inhibitor of NFB, allowing for it to disassociate 
from NFB and thus removing the inhibition of this pathway [36]. NFB is then able to 
translocate to the nucleus to exert its effects by inducing the transcription of pro-
inflammatory proteins. Similar to JNK, the inflammatory mediators needed to activate 
the NFB pathway are more readily available in an obese state, allowing for an increased 
NFB activity and increasing inflammation.  
The chronic inflammatory state of obesity, is characterized by an increased 
concentration of inflammatory cytokines as well as an increase in free fatty acids as a 
result of adipocyte expansion. As these molecules act as mediators for inflammatory 
pathways, the activation of these pathways is increased. The activation of protein kinases 
and inflammatory pathways that is present in obesity provides a direct link between 
inflammation and obesity-associated insulin resistance.  
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Inflammatory Cytokines 
 The increase in presence of inflammatory cytokines circulating systemically has 
long been linked to the pathogenesis and development of insulin resistance and type 2 
diabetes mellitus 
[37-39]
. TNF-, IL- 6 and IL-1 are expressed a high levels in obese 
individuals both in the adipose tissue and in circulation. The presence of these cytokines 
induces the activation of classic pro-inflammatory pathways including NFB and JNK 
within adipocytes, hepatocytes and macrophages 
[37-39]
. Activation of these inflammatory 
pathways contributes to the development of insulin resistance by interrupting insulin 
signaling.  
 Inflammation at the systemic level is associated with increased adiposity, which 
increases the release of TNF-, IL-6 and MCP-1 [40, 41]. Elevated MCP-1 attenuates the 
inflammatory response at the site by recruiting circulating monocytes, which differentiate 
into macrophages within the adipose tissue. TNF-α has been indicated to play a profound 
role in insulin resistance. Evidence from in vitro studies has shown that treating 3T3-L1 
adipocytes with TNF-α for 96-hours results in a significant decreased expression of 
GLUT4 and IRS- 1 compared to control 
[40]
. These results indicated the primary role of 
TNF-α in insulin resistance is in regulation of expression of genes related to insulin 
signaling.  
 IL- 6, released from both adipocytes and macrophages, is an endocrine cytokine 
that acts on tissues distant from the site of secretion. IL-6 affects the liver, bone marrow 
and endothelium. It is important in regulating the acute-phase response in the liver and 
the release of CRP, a plasma protein involved in the complement cascade 
[42, 43]
. IL-6 has 
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also been implicated to be involved in energy balance by modulating food intake and 
increasing energy expenditure, possibly attempting to regulate obesity; however, it has 
been postulated that a state of IL-6 resistance develops in obesity.   
Adipose Tissue 
Obesity is associated with the expansion of adipocytes, an increase in adipose 
tissue mass and volume, as well as a change in the distribution of adipose tissue 
throughout the body 
[37-39]
. Obesity is generally associated with higher amounts of 
visceral adipose tissue when compared with the amount of subcutaneous fat 
[38]
. The 
increase in visceral adipose tissue and overall increase in adipose tissue volume, leads to 
an increase in pro-inflammatory markers. As discussed earlier, the activation of 
inflammatory processes inhibit insulin signaling and contribute to the development of 
insulin resistance.  
Adipose tissue is a metabolically active tissue that is not only the storage site for 
extra calories in the form of triglycerides but is also an endocrine organ important in 
hormone secretion and its contribution to the development of obesity related insulin 
resistance 
[38]
. Adipose tissue is composed of pre-adipocytes, adipocytes, endothelial 
tissue and immune cells such as macrophages and monocytes, all of which are increased 
in obesity 
[5, 6]
. Supporting the adipose tissue is the stromal vascular fraction, which 
contains pre-adipocytes, smooth muscle precursors, fibroblasts, mesenchymal stem cells 
along with the immune cells macrophages and monocytes 
[5, 6]
. Increases in adiposity and 
adipocyte hypertrophy is associated with dysregulation of metabolic and endocrine 
functions which lead to alterations in the body’s physiological response, increasing 
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inflammation and diminishing insulin sensitivity 
[44,45]
. Obesity-associated inflammation 
is triggered primarily in the adipose tissue due to macrophage infiltration and increased 
secretions from adipocytes and macrophages 
[46, 47]
. Adipocytes have the ability to 
synthesize and secrete a number of bioactive molecules, known as adipokines which 
affect inflammatory processes and glucose metabolism 
[46]
.  
 Adipocytes and macrophages residing within the adipose tissue are also able to 
secrete pro-inflammatory cytokines such as TNF- α, IL-6 and leptin, which activate 
inflammatory pathways and contribute to inflammation. These inflammatory cytokines 
cause the development of insulin resistance in obesity by activating pro-inflammatory 
pathways including JNK and NFκB, inhibiting insulin signaling and preventing the entry 
of glucose into the cell.  
 Hypoxia in adipose tissue of obese individuals has also been implicated as a 
source of inflammation 
[48]. Hypoxia contributes to the activation of NFκB, regulating the 
gene expression of inflammatory cytokines and contributing to the recruitment of 
macrophages to the adipose tissue. Adipose tissue hypoxia may also contribute to the 
reduction of adiponectin and elevation of leptin seen in obese conditions 
[48]
. Inhibition of 
adipogenesis and triglyceride synthesis that is caused by hypoxia, may also contribute to 
the increased concentrations of FFA seen in obesity.  
Adipokines 
 Adipokines are bioactive compounds synthesized and released by adipocytes, and 
play an important role in inflammation, lipid metabolism and glucose homeostasis 
[47]
. 
Several adipokines are especially important in relation to the control of insulin sensitivity 
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and the development of insulin resistance.  Adipokines such as adiponectin and leptin 
have been specifically indicated as having a role insulin signaling. Adiponectin is the 
most widely released adipokine secreted by the adipose tissue and is expressed only in 
adipocytes 
[49]
.   
Plasma levels of adiponectin are reduced in obese individuals and in individuals 
with type 2 diabetes. Adiponectin in obese individuals is often deceased due to inhibition 
by the pro-inflammatory cytokine, TNF-α [45].  Adiponectin has been shown to increase 
peripheral insulin sensitivity and improve  cell insulin secretion, resulting in an increase 
in glucose uptake and utilization 
[49, 50]
. Inflammatory cytokines, specifically TNF- 
secreted by adipocytes, have been shown to have a paracrine effect and act to inhibit the 
expression of adiponectin in obese individuals 
[49]
. Research performed by Kern et al. 
found that individuals with the highest levels of adiponectin exhibited significantly lower 
TNF- mRNA expression in adipose tissue [50]. Because of the role of TNF- in the 
development of insulin resistance, adiponectin provides a protective measure from insulin 
resistance and the development of type 2 diabetes.  
Adiponectin deficient mice have been shown to become insulin resistant when fed 
a high fat diet, indicating the protective nature of adiponectin from insulin resistance 
[49, 
51]
. The under expression of adiponectin and over expression of TNF- in obesity, results 
in a vicious cycle of inflammation within the adipose tissue of obese individuals. TNF- 
secretion also results in an increased IL-6 expression within the adipose tissue which 
further aggravate the inflammatory response and increasing the likelihood of the 
development of insulin resistance.  
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 Similarly, leptin is a hormone derived from adipocytes that is important in 
regulating energy intake through its action in the hypothalamus 
[46]
. Leptin also plays a 
role in improving insulin sensitivity in peripheral tissues and increasing insulin secretion 
by the pancreatic  cells, however, these effects are generally not observed in obese 
individuals due to the development of leptin resistance 
[47]
. Leptin levels increase as 
adiposity grows, however obese individuals develop resistance to the controls of leptin in 
the hypothalamus and the catabolic effects of leptin in relation to weight maintenance. 
Leptin’s direct effects on the immune system through the stimulation of the innate 
immune system cause an increase in inflammatory conditions as leptin levels increase in 
obesity. 
 IL-6, an endocrine cytokine which targets sites distant from the area of release, is 
also secreted from cells in the adipose tissue 
[45]
. IL-6 is released from adipocytes and 
macrophages in the adipose tissue. Similar to TNF-α and leptin, the release of IL- 6 is 
increased with increasing adiposity. As mentioned earlier, IL-6 acts to regulate the 
inflammatory response of the liver by causing the release of acute phase proteins, 
specifically CRP which aids in the recruitment of host defense mechanisms. IL-6 also 
acts to increase the expression of adhesion molecules which contributes to the 
inflammation at the site and enables the attraction and adherence of macrophages to the 
endothelium.  
Macrophage Infiltration 
 Increased infiltration by macrophages into the adipose tissue is a major source of 
pro-inflammatory molecules within obese individuals. Inflammation associated with the 
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progression of obesity causes an infiltration of immune cells, specifically macrophages, 
in the adipose tissue. Pre-adipocytes have a high capacity for becoming phagocytic and 
transforming into macrophages prior to maturity 
[38, 46]
. In an obese state, increased 
expression of the cytokine, TNF-α, can induce the release of MCP-1 from pre-adipocytes. 
MCP-1 attracts monocytes and macrophages to adipose tissue. Endothelial cells within 
the adipose tissue also secrete MCP-1, further increasing infiltration of macrophages and 
inflammation. The overall change in adipocyte secretions, such as increasing leptin, 
causes the accumulation of macrophages within the adipose tissue. Adipocyte necrosis 
and hypoxia increases due to adipocyte hypertrophy in obesity which may also provide a 
mechanism for the increase in macrophages in adipose tissue 
[46]
.   
 Macrophage concentration within adipose tissue is strongly associated with 
adipocyte size and total body weight, indicating the presence of macrophage infiltration 
in obesity 
[45, 47]
. The degree of macrophage accumulation in adipose tissue is directly 
proportional to adiposity and contributes to the inflammation 
[49]
.  Gene expression 
studies have shown that macrophages are primarily responsible for the elevated 
concentration of TNF-α in obese individuals [46]. Therefore, macrophage infiltration into 
the adipose tissue is at least in part responsible for metabolic changes and inflammatory 
responses observed in obesity.   
Peroxisome Proliferator-Activated Receptors 
 Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear 
hormone superfamily of receptors which are ligand activated and act to control metabolic 
processes
[52, 53]
. Ligand-activated PPARs are important regulators of metabolic activities 
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which play a role in fatty acid metabolism, lipolysis, lipid storage and processes related to 
inflammation 
[52, 53]
. PPARs, specifically PPARγ, play a role in improving insulin 
sensitivity as well as preventing dyslipidemia and fatty liver. PPARs have also been 
shown to play an important role in repressing inflammation and have also been 
implicated as being important regulators of nutrient-gene interactions through their ability 
to recognize fatty acids and respond with regulation of lipid and glucose metabolism 
[53]
. 
PPAR activity is regulated by phosphorylation. Phosphorylation of individual 
PPARs, result in changes associated with ligand affinity, target genes, and co-factors 
needed for activation. Three different isoforms of PPARs exist, PPARα, PPARβ and 
PPARγ. These isotypes differ by tissue location, ligand preference, and affinity. 
PPARα is found primarily in the liver and acts to prevent fat build up in the liver. 
PPARα has the ability to detect levels of circulating fatty acids and respond by 
modulating lipid metabolism and the peroxisomal fatty acid oxidizing system, which is 
responsible for metabolism of very long-chain fatty acids 
[54]
. PPARα can also be 
activated by exogenous ligands such as fibrates, steroids or thiazolidinediones (TZDs). It 
has also been hypothesized that PPARα activation can occur indirectly through the 
enhanced synthesis of endogenous ligands, stimulated by an exogenous component 
[53]
. 
PPARγ is abundant in adipose tissue and plays an important role in regulating 
adipocyte differentiation and adipogenesis 
[53, 55]
. By stimulating adipocyte differentiation 
and adipogenesis, PPARγ indirectly reduces free fatty acid flux in the liver and muscle, 
therefore improving insulin sensitivity in these tissues. PPARγ also plays an important 
role in glucose metabolism not only through improving insulin sensitivity, but also by 
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increasing glucose uptake in the muscle and reducing glucose production in the liver. 
PPARγ synthetic ligands, TZDs, are currently being used in the treatment of type 2 
diabetes mellitus by improving insulin sensitivity through promoting fatty acid storage 
thereby reducing lipotoxicity 
[51]
. However, the role of PPARs in improving insulin 
sensitivity may also be associated with their ability to reduce the presence of chronic 
inflammation.  
PPARs also have an important role in repressing inflammation. PPARα and 
PPARγ have been shown to prevent NFκB activation by forming a complex with pro-
inflammatory transcription factors of this inflammatory pathway 
[55]
.  PPARs may also 
prevent NFκB activation by up regulating transcription of genes which act to prevent 
activation of the NFκB pathway, such as IKK and IκBα [55]. Due to the multiple roles of 
PPARs in improving insulin sensitivity and reducing inflammation, dietary and natural 
agonists for PPARs are being investigated to improve and prevent the development of 
various metabolic conditions, including type 2 diabetes.    
Toll Like Receptors 
 Toll like receptors (TLR) are type 1 integral membrane spanning glycoproteins 
[56, 
57]
. TLRs are protein receptors, present on either the cell surface or the endosome and are 
expressed on nearly all cells of the body, including adipocytes and immune cells such as 
macrophages and monocytes. TLRs are classified as pattern recognition receptors (PRR) 
that play a role in the activation of the innate immune system by stimulating pro-
inflammatory pathways and transcription factors in response to the presence of pathogens 
[56,57]
. PRRs have the ability to recognize pathogen-associated molecular patterns 
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(PAMPs), molecules produced only by bacteria but not eukaryotic cells 
[57]
. This ability 
allows PRRs to distinguish between self and non-self-molecules and stimulate the innate 
immune system.  
 The majority of TLR ligands are PAMPs and are diverse in structure and origin 
[56]
. Currently, there are eleven and thirteen types of TLRs that have been identified in 
humans and mice, respectively. The different types of TLRs have multiple ligands and 
may require an additional adapter protein for activation. Some ligands and adapter 
proteins for TLRs remain unidentified 
[57, 58]
. Following the binding of ligand, TLRs 
heterodimerize and undergo conformational change allowing them to initiate downstream 
signaling cascades 
[56]. 
The signaling cascades are induced either through the activation of 
the adapter protein myeloid-differentiating factor (MyD) 88 causing the production of 
inflammatory proteins, or independent of MyD88 as is the case of TLR 3 and TLR 4. The 
use of the adaptor protein MyD88 is specifically important in the relationship between 
TLRs and inflammation, as this adapter protein is responsible for the activation of 
inflammatory pathways such NFκB and the subsequent production of the cytokines TNF-
α, IL-6 and MCP-1. Among the many TLRs, TLR 4 has been especially recognized for 
its role in contributing to inflammation through the mentioned pathways. 
TLR 4 and its Role in Obesity-Associated Insulin Resistance 
 TLR 4, the most widely characterized TLR, is a protein receptor located on the 
cell membrane of several cell types including adipocytes, hepatocytes, macrophages and 
monocytes 
[58-60]
.  Ligands that activate TLR 4 include saturated fatty acids (SFA), 
endogenous free fatty acids and LPS, produced by the death of gram-negative bacteria 
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within the gut and present on the cell wall of gram-negative bacteria 
[4,61,62]
. Activation of 
TLR 4 through these ligands requires several adapter proteins such as the LPS-binding 
protein, CD14 and MyD88 as described earlier. The binding of ligands to TLR 4, results 
in the stimulation of the body’s innate immune system and initiates the inflammatory 
response. 
 TLR 4 activation can be independent or dependent of the adapter protein MyD88. 
TLR 4 is the only toll like receptor with the ability to be activated independent of 
MyD88. First evidence of the MyD88-independent pathway was revealed by Kawai and 
colleagues 
[63]
. Their work demonstrated the activation of NFκB following administration 
of LPS in MyD88 knockout mice indicating activation of TLR 4 independent of MyD88 
[63]
. TLR 4 activation independent of MyD88, is secondary to the presence of interferon 
(IFN) –β, a protein produced in response to pathogens, and leads to the production of 
inflammatory cytokines. The ability of TLR 4 to be activated dependent or independent 
of MyD88, indicates that the expression of inflammatory genes is regulated by several 
molecules during TLR 4 signaling.  
TLR 4 activation dependent on MyD88 is the classical pathway of TLR 4 
activation. Upon activation, interleukin-1 receptor-associated kinase (IRAK) is recruited 
by MyD88, leading to the activation of the NFB inflammatory pathway, resulting in an 
increased transcription of inflammatory proteins 
[5]
. Downstream signaling through 
MyD88 causes the phosphorylation of IB, the protein inhibitor of the NFB pathway, 
causing its degradation and allowing for NFB translocation to the nucleus of the cell [56]. 
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Activation of NFB results in the transcription of inflammatory genes and the induction 
of other inflammatory pathways.  
The activation of TLR 4 results in the increased presence of pro-inflammatory 
cytokines, chemokines, and ROS, all of which play a role in the innate immune system 
[57]
. TLR 4 activation increases inflammatory molecules by stimulating transcription via 
the NFκB pathway.  This increase in inflammatory markers contributes to the 
development of insulin resistance by enhancing inflammation. Due to its contribution to 
the inflammatory state, TLR 4 has been implicated as a potential mechanism through 
which obesity contributes in the development of insulin resistance.  
 TLR 4 is recognized as an important link between a dysregulated immune system 
and the development of insulin resistance, especially when associated with obesity 
[60-62]
. 
It is well established that TLR 4 contributes to insulin resistance through activation of the 
NFκB pathway; however TLR 4 can also induce the inflammatory response 
independently of NFκB [57]. For example, TLR 4 is involved in regulating the activation 
of JNK, an important protein kinase in the modulation of insulin resistance. The role of 
TLR 4 in inducing inflammation, which alters insulin signaling, makes it a key player in 
the development of obesity-associated insulin resistance.  
TLR 4 activation is increased in obesity, especially when coupled with the 
consumption of a high fat diet, due to an increase in the presence of ligands for the 
receptor and an increase in number and size of cells containing the receptor. Obesity is 
associated with an increase in adipocyte number and size as well as macrophage 
infiltration into the adipose tissue. Both macrophages and adipocytes readily express TLR 
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4, resulting in an increase in TLR 4 expression in obese individuals. Nutrient excess, a 
diet rich in saturated fat, and an increase in circulating endogenous FFA due to lipolysis, 
all provide ligands for TLR 4 activation 
[61, 65]
. The increase in ligand availability as well 
as the increased expression of TLR 4, leads to a higher amount of TLR 4 activation and 
the chronic inflammation seen in obesity.      
C3H/HeJ Animal Model 
 The use of the C3H/HeJ animal model has been important in determining the role 
of TLR 4 in the development of obesity-associated insulin resistance through regulation 
of the innate immune system. C3H/HeJ mice contain a defect in their response to LPS 
through a mutation in the cytoplasmic domain of TLR 4 His
712 
of the TLR 4 protein 
whereas wild-type or LPS-responsive animals would possess a proline 
[61, 62]
. Due to this 
mutation, C3H/HeJ mice have been shown to have an altered response to a high fat diet, 
such as improved glucose tolerance and body composition when fed a high fat diet 
[4, 66-
68]
. These results demonstrate that TLR 4 plays an important role in the development of 
obesity-associated insulin resistance.  
Suganami et al.(2007) compared the effects of a high fat diet (60% kcal from fat) 
versus a standard chow diet (5.4% kcal from fat) in wild-type (C3H/HeN) and TLR 4 
deficient mice (C3H/HeJ) 
[66]
. After feeding for 16 weeks, C3H/HeJ mice showed 
significantly lower glucose and insulin levels, indicating improved insulin sensitivity 
compared to wild-type mice. C3H/HeJ mice also showed higher adiponectin 
concentrations and reduced FFA levels when fed a high fat diet compared to standard 
chow diet. Lower FFA concentrations, indicates an improved insulin response due to 
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insulin’s role in regulating lipolysis. Their findings demonstrate that TLR 4 plays a 
critical role in modulating obesity-associated insulin resistance. 
 Suganami et al. was also able to demonstrate an improved inflammatory response 
within the adipose tissue of C3H/HeJ mice compared to the wild-type mice when fed a 
high fat diet 
[66]
. Similar results were observed by Poggi et al. who showed a reduction of 
the inflammatory response in adipocytes and macrophages of cells from C3H/HeJ mice 
fed a high fat diet 
[4]
. These results indicate that TLR 4 plays a role in controlling obesity-
associated insulin resistance both at the systemic and tissue level.  
A similar study by Tsukumo et al. (2007) showed that TLR 4 deficient mice 
(C3H/HeJ) had a significantly lower body weight and epididymal fat pad weight 
compared to wild-type (C3H/HeN) mice when fed a high fat diet (55% kcal from fat) 
[68]
. 
Adiponectin levels were also significantly decreased in C3H/HeN mice but not in 
C3H/HeJ mice 
[66, 68]
. C3H/HeJ on the high fat diet also showed an improved glucose 
tolerance following an intraperitoneal glucose tolerance test (IGTT) compared wild type 
mice fed a high fat diet.  Not only were improvements seen in weight and glucose 
control, improvements in the inflammatory response was also observed. C3H/HeJ mice 
exhibited reduced activation of the inflammatory pathways NFκB and JNK, which are 
commonly induced following high fat diet feeding 
[68]
. These findings indicate that TLR 4 
deficiency prevents the development of obesity-associated insulin resistance and 
induction of inflammation when mice are fed a high fat diet.  
Overall, studies using the C3H/HeJ model, a model of TLR 4 deficiency, have 
shown improved glucose tolerance, insulin sensitivity and an improved body composition 
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as well as a reduced inflammatory response. These results indicate the important role of 
TLR 4 in obesity-associated insulin resistance. Based on these findings, we chose to use 
the C3H/HeJ model in the present study to investigate whether bitter melon could prevent 
or delay the development of insulin resistance by preventing the activation of TLR 4.   
Phytochemicals 
 Phytochemicals are defined as non-nutrient or secondary metabolites that provide 
color and taste in fruits and vegetables but play no role in growth or development of 
plants 
[69]
. Unlike vitamins and minerals, there are no current recommendations for the 
consumption of phytochemicals; however their use in preventative medicine has recently 
been a subject of extensive research 
[70]
.  Phytochemicals are hypothesized as a 
significant factor in preventing or delaying the development of disease 
[70]
.  While 
specific data regarding individual phytochemicals is limited, the role of phytochemicals 
as anti-inflammatory agent and their role in the prevention of chronic diseases such as 
type 2 diabetes and cardiovascular disease is extensive 
[71]
. Phytochemicals have various 
mechanisms of action to exert their health benefits. Besides their action as an antioxidant 
to diminish oxidative damage, phytochemicals, may also act as hormones or to stimulate 
enzymatic action 
[71]
. 
 Polyphenols are the most relevant group of phytochemicals in regards to their role 
in providing extensive health benefits 
[72]
. Polyphenols are made up of several different 
classes, lignans, flavonoids, phenolic acids, stilbene, and xanthones, all of which are 
found in various fruits, vegetables, beverages and spices 
[73]
. While the use of 
polyphenols in the prevention of chronic disease is widespread, the use of polyphenols in 
relation to obesity is especially prevalent 
[71]
. 
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 Polyphenols: Role in Inflammation, Obesity and Insulin Resistance  
 Diet with a higher nutrient density has been reported to reduce body weight and 
improve obesity-related conditions 
[73]
. This indicates that intake of certain food 
components play a role in preventing obesity-related inflammatory diseases. Polyphenols 
are used as a multi-targeted remedy, due to their various mechanisms of action, against 
the development and progression of insulin resistance and type 2 diabetes mellitus 
[70]
. 
Polyphenols act as antioxidants, anti-inflammatory agents as well as being key players in 
regulating glucose and lipid metabolism 
[71]
. 
 Bioactive food components exert their health benefits through several different 
mechanisms. These mechanisms include modulation of the NFκB, JNK and PPAR 
signaling pathways. Some polyphenols, such as resveratrol, have been implicated as 
ligands for PPARγ, interfering with the activation of the pro-inflammatory pathway 
NFκB and preventing the transcription of inflammatory genes [73]. Polyphenols such as 
resveratrol and quercetin have been shown to reduce NFκB and JNK activation, both of 
which contribute to the development of insulin resistance 
[74]
. Polyphenols like genistein 
and amentoflavone have also been noted to enhance the gene expression of PPAR’s [73].    
In addition to attenuating the inflammatory response, polyphenols act as antioxidants by 
chelating metals, scavenging free radicals, and inhibiting free radical generation. 
Inhibition of oxidative stress and inflammation by phenolic compounds delays or 
prevents the development of obesity-related insulin resistance due to the prevention of 
cell damage 
[75]
.   
Certain polyphenols have been shown to directly influence insulin sensitivity and 
glucose uptake. Quercetin, from bitter melon juice, for example enhances glucose uptake 
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in muscle cells 
[73]
. Common spices such as cinnamon and cloves have exhibited insulin-
like qualities 
[73]
. There are many on-going studies examining the use of phytochemicals 
and bioactive food components in reducing insulin resistance. One functional food that 
has shown promise in improving insulin sensitivity is bitter melon. Therefore we 
investigated the use of bitter melon in modulating insulin resistance in a model of diet-
induced obesity.                                                                                                                                                                
Bitter melon (Momordica charantia, MC) 
 Bitter melon (Momordica charantia, MC) also known as bitter gourd or balsam 
pear, is a tropical vegetable belonging to the cucurbitaceous family, including cucumbers, 
melons and gourds. MC is known for its bitter taste, which is enhanced as it ripens. MC is 
popular in Asian countries and has been widely used in traditional medicine as an anti-
diabetic remedy throughout the world. Specifically, MC has been used by the indigenous 
populations in areas such as South America, India and Asia as a hypoglycemic agent 
[76]
. 
MC has been demonstrated to not only provide hypoglycemic effects, but has also been 
used as an anti-cancer, anti-viral and anti-inflammatory agent 
[77]
.  
Composition 
 Bitter melon contains significant amounts of micronutrients such as vitamin C, 
folate, calcium and magnesium, as well as being a good source of dietary fiber 
[78, 79]
.  
MC also contains phytochemicals such as polypeptide-p, charantin, and vicine, all of 
which have been demonstrated to have insulin-like properties and aid in controlling blood 
glucose levels in diabetics 
[79]
. Nutrient composition of the bitter melon variety used in 
this study can be found in Table 1.  
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A variety of phytochemicals have been isolated from the fruit, seeds and the 
whole MC plant. Charantin, containing sitosterol and stigmastadienol glucosides, has 
been implicated in being responsible for the hypoglycemic effects of MC, with the exact 
mechanism of action remaining unknown 
[77]
. Vicine, isolated from the seeds of the plant, 
has also been shown to provide a hypoglycemic response when administered orally 
[77]
. 
The isolated fraction from bitter melon, polypeptide-p, also referred to as p-insulin or v-
insulin, has been most widely indicated as an insulin analog in both animal models and 
clinical trials of diabetes 
[80]
.  Other bioactive compounds have been isolated and 
contribute to the health benefits of bitter melon consumption, for example the component 
momordin, an oleanolic acid glycoside has been shown to contribute to the anti-tumor 
effects of bitter melon 
[81]
.  
Studies on Health Benefits of Bitter Melon  
Bitter melon has not only been used in Ayurvedic and traditional medicine, but 
has also been indicated as being potentially important in “westernized” medicine. Bitter 
melon has been investigated in association with a variety of health benefits, including its 
role in reducing inflammation, improving lipid parameters and most notably reducing the 
severity and preventing the development of insulin resistance 
[77, 81]
. The various health 
benefits of MC have been demonstrated in models of human disease as well as in in vivo 
models.  
 The anti-inflammatory effects of MC extract in macrophage-like cells were 
investigated by Kobori et al. 
[82]
. Raw 264.7macrophage-like cells were treated with LPS 
to induce inflammation in combination with a butanol extract of MC 
[82]
. The MC butanol 
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fraction reduced the production of TNF-α and the activity of NFκB and JNK, common 
inflammatory intermediaries induced by LPS 
[82]
. Bitter melon juice was shown to reduce 
inflammation by increasing anti-inflammatory cytokine secretion when administered to 
peritoneal macrophages concurrently with LPS 
[83]
. However, a high dose of bitter melon, 
500 µg/mL was needed to exert the anti-inflammatory effect.  
The effect of MC in animal models of chronic conditions have also been 
investigated. For example, the effect of supplementation with a 3% (w/w) bitter melon 
seed diet for 100 days were investigated in female Zucker rats, a commonly used model 
of obesity 
[84]
. This study showed the ability of MC to down-regulate the expression of 
NFκB within adipose tissue of obese mice. Bitter melon seed supplementation also 
reduced total cholesterol and low-density lipoprotein cholesterol. This work exemplifies 
the anti-inflammatory properties of bitter melon seeds and the possible cardio protective 
role of bitter melon.  
Bitter melon has also been shown to improve lipid metabolism in animal models 
[85, 86]
. Senanayake and colleagues investigated the effects of different dried MC fruit 
dosages and methanol extracts of various MC varieties in male Sprague-Dawley rats
 [86]
. 
The methanol extract of the Koimidori variety was most effective in lowering hepatic 
triglyceride concentrations and serum triglyceride concentrations 
[86]
. In a study 
performed by the same research group, male Sprauge -Dawley rats that were given the 
same methanol extract of the Koimidori variety in various amounts (0.5, 1 and 3% w/w) 
showed a dose-dependent improvement in liver triglyceride and cholesterol levels 
[86]
.  
These results highlight the role of MC in attenuating the development of atherosclerosis 
and non-alcoholic fatty liver disease. 
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MC has also been demonstrated to control weight gain and reduce visceral fat 
mass accumulation in rats 
[87, 88]
. This study was performed using female Sprague-Dawley 
rats that were either fed a high fat or low-fat diet for 6 weeks. At week 7, the low-fat 
group was switched to high fat,  however, those on high fat diet were switched to a high 
fat diet containing different amounts of freeze-dried bitter melon powder (0.375, 0.75 or 
1.5% w/w). Rats fed a high fat diet with bitter melon (0.75 and 1.5% w/w) exhibited an 
improved glucose tolerance following an oral glucose tolerance test, however no 
significant changes in body weight or fat mass was observed 
[87]
.  A separate experiment 
was conducted using male Sprague-Dawley rats that were randomly assigned to a high fat 
or low-fat diet and at 5 weeks the high fat fed animals were assigned to three different 
levels of MC (0.375%, 0.75%, or 1.5% w/w) 
[87]
.  The results of this study showed the 
ability of MC to significantly reduce fat mass, which contributed to the reduced free fatty 
acid concentrations as well as lower serum insulin and leptin concentrations. The 
reduction in fat mass also contributed to the ability of MC to improve glucose tolerance 
in this animal model 
[87]
.  
Bitter Melon and Glucose Homeostasis 
 While research in humans is limited, overwhelming amounts of research verify 
the hypoglycemic effect of bitter melon in animal models 
[81, 88-90]
. However, the 
mechanism through which the active components of MC act is unclear. Suggested 
hypoglycemic mechanisms of action include inhibition of glucose absorption, improved 
glucose utilization by the liver, adipose tissue and skeletal muscle as well as a possible 
improvement in insulin action 
[89]
. MC also affects the regulation of PPAR and PPAR, 
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which play a role in glucose metabolism and lipid homeostasis 
[83]
. Alterations in the 
PPAR and PPAR pathways are linked to the pathogenesis of insulin resistance [83].  
Several animal studies have shown the role of MC in regulating glucose 
homeostasis through a PPAR mediated pathway 
[84, 88]
. A study performed by Gadang et 
al. using Zucker rats showed that MC seeds increased the expression of PPAR in white 
adipose tissue 
[84]
. Bitter melon also had the ability to down-regulate several targets of 
PPAR, including reducing the expression of NFκB [84].  
 An animal study using male C57BL/6J mice, gave evidence to the role of MC in 
regulating the PPAR mediated pathway 
[89]
. This study analyzed the effectiveness of MC 
compared to rosiglitazone, a type of TZD prescribed in the treatment of type 2 diabetes, 
in improving glucose homeostasis in mice fed a high fat diet. The researchers observed 
that bitter melon, increased the expression of PPAR in adipose tissue, leading to the 
increased uptake of glucose and lowered expression of leptin. This study demonstrated 
the role of MC in improving glucose homeostasis and regulating adipocyte differentiation 
similar to the action of TZDs 
[83]
. Similar research using a fructose-induced diabetes 
model in male Sprague-Dawley rats, attributed the role of MC in improving insulin 
resistance to increased mRNA expression of PPAR in white adipose tissue. Sprague-
Dawley rats were fed a control or high-fructose (60% fructose) diet for 8 weeks and were 
then subdivided into six different treatment groups where they were fed varying doses of 
MC or rosiglitazone 
[90]
. Addition of MC to a high-fructose diet, increased protein 
expression of GLUT 4 in the skeletal muscle and prevented fructose-induced leptin 
abnormalities, both of which contributed to improved insulin sensitivity 
[90]
.   
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 Other signaling pathways involved in glucose homeostasis have also been shown 
to be altered by bitter melon. Tan et al. showed that MC activated the AMPK pathway 
which stimulated GLUT 4 translocation from the cytosol to the cell membrane to 
improve glucose uptake and enhance insulin sensitivity in skeletal muscle 
[91]
. MC has 
also been shown to reverse the inhibition of tyrosine phosphorylation of the insulin 
receptor substrate (IRS) 1, a common dysregulation on insulin signaling present in insulin 
resistant individuals 
[92]
. The various modes of action in which MC is able to act indicate 
its multiple roles in attenuating insulin resistance and the deregulation of glucose 
homeostasis.  
 The role of bitter melon in controlling glucose homeostasis and improving insulin 
sensitivity has been compared with the use of prescribed medications commonly used in 
patients with type 2 diabetes mellitus. When compared to Metformin in a clinical trial, 
bitter melon improved fructosamine concentrations in patients, however no effect was 
exhibited on fasting plasma glucose levels or the ability of the body to clear glucose in an 
oral glucose tolerance test 
[93]
. Therefore, it is important to note that further research is 
needed to determine dosages and methods of supplementation of bitter melon appropriate 
in humans to obtain similar results seen in animal studies. 
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CHAPTER III 
 
 
METHODOLOGY  
 This study was designed to determine the dose-dependent effects of bitter melon on 
glucose homeostasis, body composition, and lipid parameters in mice fed a high fat diet. This 
study also examined the effects of TLR 4 on high fat diet induced obesity, inflammation and 
insulin resistance, therefore the C3H/HeJ strain was used.  
Animal Care and Dietary Treatment  
The Institutional Animal Care and Use Committee (IACUC) at Oklahoma State 
University approved the protocol for this animal study. Eight-week old male C3H/HeJ 
mice (n=48) were purchased from Jackson Laboratories (Bar Harbor, ME) and C57BL/6 
mice (n=49), were purchased from Charles River Laboratory (Kingston, NY). Mice were 
housed in an Oklahoma State University (OSU) animal research facility in a climate-
controlled room with a 12hr light/dark cycle. After 7 days of acclimation, mice from each 
strain were randomly divided into four dietary treatment groups (n=12-13/group): control 
with 10% kcal from fat, high fat (HF) with 60% kcal from fat, HF +1% (w/w) freeze 
dried bitter melon (MC) and HF + 10% (w/w) freeze dried MC.  
Bitter melon was purchased from a local ethnic grocery store, washed, dried, 
seeds were removed, cut into smaller pieces, freeze-dried and ground before being 
incorporated into the diet. The control diet was based on the AIN-93M diet (Reeves, 
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1993). The macronutrient, calcium, and phosphorus content of MC were analyzed by 
Nestle Purina Analytical Laboratories (St. Louis, MO). Contributions of MC were 
adjusted to assure that all HF diets had similar macronutrient, calcium, and phosphorus 
content. Composition of MC and experimental diets used in this study and of MC can be 
found in Tables 1 and 2, respectively. Mice had access to food and deionized water ad 
libitum. Food intake was monitored three times per week and body weights were 
measured on a weekly basis. Dietary treatment lasted for nine weeks.   
Glucose Tolerance Test 
 After 8 weeks of dietary treatment, a glucose tolerance test was performed. 
Following a 6 hr fast, mice were administered an intraperitoneal injection of 20% glucose 
solution (2 g glucose / kg of body weight). Blood samples were obtained from the tail 
vein and glucose concentrations were measured at 0, 5, 15, 30, 60 and 120 minutes post 
glucose injection using an AlphaTrak blood glucose monitoring system (Abbot 
Laboratories, Chicago, IL).  
Necropsy, Tissue Collection and Storage 
 After 9 weeks of dietary treatment, following a 6 hr fast, mice were anesthetized 
with ketamine/xylazine cocktail (10 mg/ml ketamine and 1 mg/mL xylazine) with a 
dosage of 0.006 mL/gram of body weight. Body composition and bone density were 
measured using dual energy x-ray absorptiometry (GE Lunar Piximus, Fitchburg, WI). 
Blood was collected from the carotid artery and placed in a 1.5 mL microcentrifuge tube 
coated with an anticoagulant, ethylenediamine tetraacetic-acid (EDTA). Liver, visceral 
and peri-renal white adipose tissue, thymus, spleen, and kidneys were collected and 
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weighed. Portions of the tissues were stored in 10% neutral buffered formalin (NBF) and 
the remainder was snap frozen in liquid nitrogen and stored at -80ºC for further analyses. 
Plasma was obtained by centrifugation of whole blood for 20 min at 4 x g, aliquot and 
stored at -80C for later use. 
Clinical Parameters of Inflammation and Diabetes 
Plasma triglycerides, total cholesterol, fructosamine, glucose and high-density 
lipoprotein (HDL) concentrations were determined using the BioLis24i clinical analyzer 
(Carolina Liquid Chemistries Corporation™, Brea, CA). Reagents were purchased from 
Carolina Liquid Chemistries Corporation™ (Brea, CA) with the exception of NEFA 
which was purchased from Wako Diagnostics (Richmond, VA). 
 Measurement of triglyceride concentrations were determined by mimicking the 
hydrolysis of fatty acids to glycerol in the liver. Plasma triglycerides were hydrolyzed to 
form free fatty acids and a glycerol. Glycerol was then phosphorylated by glycerol-1-
phosphate which produced hydrogen peroxide (H2O2) which reacts with p-chlorophenol 
and 4-aminoantipyrine to yield a red color quinoneimine. Change in absorbance was 
measured as 505/692 nm, which represented the concentration of triglycerides in the 
sample (Carolina Liquid Chemistries Corporation™, Brea, CA).  
 To determine total cholesterol, cholesterol was hydrolyzed by cholesterol 
esterase to free cholesterol and free fatty acids, forming H2O2  . Total cholesterol is 
further esterified by cholesterol esterase; in this reaction H2O2 was formed. Hydrogen 
peroxide then reacts with 4-aminoantipyrine and p-hydroxyenzoate to form red color 
quinoneimine. The red color formed absorbs at 500 nm and is directly proportional to the 
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cholesterol concentration in the sample. Glucose concentrations were determined by the 
use of the enzymatic hexokinase and glucose-6-phosphate dehydrogenase reaction in the 
presence of magnesium where glucose-6 phosphate and adenosine diphosphate (ADP) are 
produced. Glucose-6-phosphate dehydrogenase acts to oxidize glucose-6-phosphate and 
NAD
+
 to form 6-phosphogluconate and NADH. The amount of NADH produced is 
proportional to the amount of glucose present in the plasma, NADH absorbs at 340 nm 
which is proportional to the amount of glucose in the sample (Carolina Liquid 
Chemistries Corporation™, Brea, CA) 
To determine HDL concentrations, HDLD detergent is added to plasma samples, 
solubilizing the HDL fraction and allowing HDL to be released. Concentrations of HDL 
are determined by the interaction of HDL with cholesterol esterase, cholesterol oxidase 
and chromogens to from color. The color produced, which absorbs at 600 nm, is 
proportional to HDL cholesterol in the sample (Carolina Liquid Chemistries 
Corporation™, Brea, CA).  
Plasma non-esterified free fatty acids (NEFA) concentrations were measured 
using a colorimetric assay kit following the manufacturer’s instructions. In the presence 
of ATP and CoA, NEFA are converted to thiol esters of CoA by acyl-CoA synthetase. 
Acyl-CoA is then oxidized and H2O2 is produced as a byproduct which allows for 
condensation and the formation of purple color. The color produced absorbs at 550 nm 
which is proportional to NEFA concentrations (Wako Diagnostics, Richmond, VA). 
Fructosamine levels were analyzed to indicate glycemic control over the prior 2-3 
weeks. Fructosamine concentrations were determined by a colorimetric procedure based 
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on the ability of ketoamines to form formazan dye. Nitroblue tetrazolium (NBT) is 
reduced to a formazan dye when reagent is added to the plasma sample; the rate of 
formazan dye formation is proportional to fructosamine concentration based on the 
absorbance at 505 nm (Carolina Liquid Chemistries Corporation™, Brea, CA).  
Hemoglobin A1c (HbA1c) levels were analyzed in whole blood samples collected 
with EDTA anticoagulant utilizing an antigen and antibody reaction using a commercial 
kit (Carolina Liquid Chemistries Corp., Brea CA). Over time, hemoglobin A1C is formed 
by the addition of glucose to the end of the hemoglobin chain allowing this measure to 
indicate the control of blood glucose levels in diabetic individuals. The reagents, mouse 
antihuman HbA1c monoclonal antibody and goat anti-mouse IgG polyclonal antibody are 
added allowing for agglutination. Agglutination is proportional to the amount of HbA1c 
absorbed on latex particles which is then measured as absorbance at 660 nm. 
 Plasma leptin and adiponectin levels were measured using a double antibody 
sandwich enzyme-linked immunosorbent assay (ELISA) using a commercial kit (R&D 
Systems, Minneapolis, MN) following the manufacturer’s instructions. The principle of 
this assay involves the capture and concurrent binding of the given molecule, leptin or 
adiponectin in this case and the absorbance is measured, which is directly proportional to 
the amount of bound analyte. Concentrations of TNF- were measured by a Quantikine 
immunoassay kit, a solid phase ELISA (R&D Systems, Minneapolis, MN). Briefly, this 
kit contains a plate pre-coated with a monoclonal antibody specific for the mouse TNF-α. 
When samples are added, mouse TNF-α is bound by the antibody. After washing, and 
adding a stop solution, the intensity of the color is measured, by absorbance, which is 
proportional to the amount of TNF-α present in the sample (R&D. Minneapolis, MN).  
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Total RNA Extraction 
 Total RNA was extracted from liver and visceral white adipose tissue samples 
(n=6/group) of mice using RNA STAT-60 reagent (Tel-test Inc., Friendswood, TX) and 
protocol (AMS Biotechnology, Lake Forest, CA). Briefly, samples were homogenized in 
1 mL of STAT-60 reagent/100 mg of tissue. Following homogenization, samples were 
allowed to sit for 5 min on ice, and then chloroform (200 µL/1 mL of STAT-60) was 
added and allowed to sit for 3 min to aid in phase separation. Samples were centrifuged 
for 15 min at 1  x g at   C, and the colorless aqueous phase was transferred to a new 
centrifuge tube. Isopropanol (0.5 mL/1 mL STAT-60) was added and samples were 
allowed to precipitate on ice for 30 min. Samples were centrifuged again for 10 min at 1  
x g at   C , isopropanol was decanted and 75% ethanol (1 mL/1 mL STAT-60) was used 
to wash and remove remaining contaminants. Samples were centrifuged for 5 min at 1  x 
g at   C, ethanol was decanted and RNA was dissolved in diethylpyrocarbonate (DEPC) 
treated water.  
 The integrity of the total RNA was analyzed using 1% agarose gel 
electrophoresis to assure the presence of 18S and 28S bands with ethinium bromide 
staining. The RNA concentration (ng/μL) was determined by analysis of optical density 
at 260/280 nm using a NanoDrop Analysis machine (Thermo Scientific, Wilmington, 
DE). 
Real-Time Polymerase Chain Reaction (PCR) 
 Following extraction of total RNA from the liver and WAT, complementary DNA 
(cDNA) was synthesized. This cDNA was then used for real-time PCR. Real-time PCR 
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was performed using two pathway focused RT
2 
Profiler PCR arrays purchased from 
Qiagen (Qiagen, Valencia, CA). The manufacturer’s instructions were followed. The 
following arrays were used to determine gene expression of particular interest; PPAR and 
toll-like receptor signaling in the liver and white adipose tissue respectively. Liver 
samples of C57BL/6 mice from each dietary treatment group (n=4/group) were used for 
the PPAR array. White adipose tissue samples of HF and HF + 10% BM groups 
(n=4/group) of both strains (C57BL/6 and C3H/HeJ) were used for the toll-like receptor 
signaling array.  
Liver Histology 
 Portions of liver were stored in 10% neutral buffered formalin for histology. Liver 
portions (n=6/group) were dehydrated through a graded ethanol series using a Thermo 
Scientific Shandon-Citadel 1000 tissue processor (Austin, TX) and then embedded in 
paraffin wax using the Leica EG1160 paraffin embedder (Buffalo Grove, IL). Samples 
were sectioned into 7 µm thicknesses using the high performance Leica RM 2165 
microtome (Buffalo Grove, IL) and stained using a hematoxylin and eosin (H&E) stain. 
Stained liver samples were scored based on degree of steatosis and inflammation. Liver 
samples were analyzed and scored by a pathologist (Dr. Stan Lightfoot, Department of 
Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK). 
The degree of steatosis was graded on a scale of 0-4, 0 indicating no steatosis and 4 
indicating excessive steatosis.  
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Statistical Analyses 
 Data was analyzed using SAS version 9.2 (SAS Institute Inc., Cary, NC). Data 
was analyzed using a 2X4 factorial; results were reported as mean ± standard error of the 
mean and considered statistically significant if the p-value was less than 0.05. Categorical 
data derived from the pathology scoring were compared using a chi-square test followed 
by Fisher's Exact Test to confirm the significance. Results of the PCR array were 
analyzed using online software (RT
2
 Profiler PCR Array Data Analysis version 3.5) from 
SABiosciences (Qiagen, Valencia, CA); results were compared to the set control with a 
p-value less than 0.05 considered statistically significant.  
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CHAPTER IV 
 
 
FINDINGS  
Effects of Bitter Melon and TLR 4 on Body Weight and Food Intake (Table 3 and 
Figure 1) 
 Prior to initiation of dietary treatment, there were no significant differences in 
body weights between strain or dietary treatment groups. Significant differences in body 
weights were observed starting at week two of dietary treatment (Figure 1). After 90 days 
of dietary treatment, C3H/HeJ mice had a significantly higher body weight compared to 
C57BL/6 mice. Mice that received the high fat (HF) and HF + 1% MC had similar final 
body weights and were higher than the control group and HF + 10% MC group. The 
control group has the lowest final body weight, while the HF + 10% MC had a final body 
weight in between the HF and control groups (Table 3).  
While there was a difference in final body weight between the two strains, no 
significant difference in caloric intake was observed (Table 3). Therefore, the difference 
in body weight between the two strains cannot be explained by the differences in food 
intake. The HF + 1% MC had the highest caloric intake, followed by the HF + 10% MC 
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which was similar to the HF group. As expected, the control group had the lowest caloric 
intake.  
Effects of Bitter Melon and TLR 4 on Relative Tissue Weights (Table 4) 
 Tissue weights were analyzed relative to body weights to normalize the changes 
in body weight. Peri-renal white adipose tissue (WAT) relative weights were significantly 
lower in C3H/HeJ mice, however no difference was observed in visceral WAT relative 
weights (Table 4). In both strains, HF + 10% MC significantly reduced the accumulation 
of fat in the visceral and peri-renal regions compared to mice in the HF and HF + 1% MC 
groups, though not to the level of control animals. Relative thymus and kidney weights 
also differed among strains; C3H/HeJ mice had higher kidney weights and lower thymus 
weights compared to C57BL/6 mice (Table 4). No significant differences in relative 
spleen and liver weights were observed between strains. HF + 10% MC reduced relative 
liver and thymus weights and had no effect on relative kidney weights in both strains of 
mice.  
A significant interaction effect was observed between diet and strain in the 
relative weight of peri-renal WAT (Table 4). Bitter melon, in both 1% and 10% 
increments, had lower peri-renal WAT weights in C3H/HeJ mice compared to C57BL/6 
mice. Also, the high fat diet had less of an effect on C3H/HeJ mice compared to C57BL/6 
mice in regards to lipid accumulation and adipocyte expansion in peri-renal WAT 
regions, indicating a diet effect as well as a strain effect. 
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Effects of Bitter Melon and TLR 4 on Body Composition (Table 5) 
 Body composition was measured prior to sacrifice to determine effect of diet and 
strain. C3H/HeJ mice had a significantly higher body fat percentage and a lower lean 
body mass (LBM) percentage compared to C57BL/6 mice, which is consistent with the 
findings of Poggi and colleagues 
[4]
. However, C3H/HeJ mice also exhibited an increased 
bone mineral density (BMD) and content (BMC), and area (BMA) compared to C57BL/6 
mice (Table 5). 
An effect of dietary treatment was also observed in regards to body composition. 
Mice fed a diet with HF + 10% MC but not HF + 1% MC, were shown to have a lower 
body fat percentage and a higher LBM percentage when compared to other high fat 
groups (Table 5). Mice fed a HF + 10% MC were also shown to have higher BMC and 
total bone area in both strains of mice, compared to the HF + 1% MC. There was no 
difference in BMD between dietary treatments.  
Effects of Bitter Melon and TLR 4 on Plasma Lipid Parameters (Table 6) 
  Clinical lipid parameters were analyzed to determine the role of TLR 4 and bitter 
melon in lipid metabolism. C3H/HeJ mice were shown overall to have significantly 
higher lipid levels when compared to C57BL/6 mice. Specifically, total cholesterol and 
triglyceride levels were elevated in the TLR 4 deficient strain (Table 6). However, 
C3H/HeJ also had elevated HDL cholesterol levels. The levels of non-esterified fatty 
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acids (NEFA) levels in C3H/HeJ mice were significantly lower compared to C57BL/6 
mice, which may be related to improved insulin sensitivity.  
 When comparing the effects of dietary treatment, mice fed the HF + 10% MC diet 
showed improved lipid profiles. Cholesterol and triglyceride levels of mice fed the HF + 
10% MC diet were significantly lower compared to HF and HF + 1% MC groups (Table 
6). However, the protective cholesterol, HDL, was also significantly lower which 
contributed to the reduced cholesterol levels. Interestingly, triglyceride levels of mice fed 
the HF + 10% MC were significantly lower than the mice fed the control diet. These 
results indicate the beneficial effect on lipid parameters of supplementing a high fat diet 
with bitter melon in 10% dose.   
Effects of Bitter Melon and TLR 4 on Parameters Related to Glucose Metabolism 
(Tables 7 and Figure 2) 
Clinical parameters related to glucose metabolism were analyzed to determine the 
effects of bitter melon and TLR 4 on glucose metabolism and utilization. Hemoglobin 
A1C (HbA1C) was analyzed to determine the effects of bitter melon and TLR 4 on 
overall glucose control (Table 7). C3H/HeJ mice were shown to have a significantly 
lower HbAIC level compared to C57BL/6 mice, indicating improved glucose control in 
the long-term and a possible role of TLR 4 activation playing a role in glucose utilization. 
Fructosamine was also analyzed to determine a similar affect; however fructosamine is 
more indicative of short-term glucose control in mice. Fructosamine was significantly 
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lower in C3H/HeJ mice than in C57BL/6 mice, again indicating improved glucose 
control in these mice (Table 7). There was no effect of diet on HbA1C or fructosamine 
levels, indicating no effect of bitter melon on glucose metabolism; however, the 
experimental period may not have been long enough to induce a dietary effect as the 
turnover of red blood cells which contributes to HbA1C levels is every 3 months.  
A dietary treatment effect was seen on fasting blood glucose levels while no 
difference was observed between the two strains. Mice fed the HF + 10% MC had the 
lowest blood glucose concentrations and were comparable to the control group; 
indicating a positive effect of bitter melon on glucose metabolism.  
 A glucose tolerance test was performed at 8 weeks of dietary treatment and total 
area under the curve (AUC) was calculated to compare the overall glucose response due 
to dietary treatment and strains. There was a significant difference in glucose at all-time 
points of the glucose tolerance test except at 15 minutes post-glucose injection (Figure 2). 
Mice fed the HF + 10% MC diet had significantly lower total AUC compared to HF and 
HF + 1% MC and similar to mice fed the control diet. A lower total AUC indicates the 
body’s ability to clear circulating glucose at a faster rate compared to other groups. 
C3H/HeJ mice had a significantly lower total AUC compared to C57BL/6 mice, again 
indicating an improved response in the periphery to circulating glucose (Table 7). An 
interaction between diet and strain was also observed in regards to total AUC. Bitter 
melon, specifically in a 10% dosage, was able to significantly improve the blood glucose 
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response of C3H/HeJ mice to the level mice fed the control diet. Also, C3H/HeJ mice fed 
a high fat diet alone, had a significantly lower total AUC compared to C57BL/6 mice fed 
a high fat diet. These results indicate not only an effect of diet on the glucose response 
but also an effect of strain and more specifically, TLR 4.  
Effects of Bitter Melon and TLR 4 on Liver Steatosis and Inflammation (Table 8) 
 Liver and white adipose tissue histology samples were analyzed by a pathologist, 
Dr. Stan Lightfoot. There was not a significant amount of inflammation observed within 
the liver of the animals in either strain or diet. There was also no difference between 
strain on degree of liver steatosis. However, significant differences were observed 
between diets in the degree of liver steatosis. Mice fed the HF + 10% MC diet had lower 
degree of steatosis compared to mice fed the HF or HF + 1% MC diet, confirmed by a 
Fisher’s Exact Test (p = 0.0054). Interestingly, mice that received the HF +10% MC diet 
had lower degree of liver steatosis compared to those that received the control diet. 
Effects of Bitter Melon and TLR 4 on Gene Expression 
 The PPAR PCR array was analyzed in the liver of C57BL/6 animals and results 
were compared to the group fed a high fat diet without bitter melon. Bcl2l1, a member of 
the BCL-2 family, was up regulated in the HF + 10% MC group. The family of BCL-2 
proteins play a role in regulation of apoptosis, or programmed cell death. Our results 
might indicate an increase in apoptosis in the liver of these animals 
[89]
. Significant results 
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were also found in relation to insulin signaling. PDPK1, also known as PDK-1 or 3-
phosphoinositide-dependent protein kinase-1, was significantly increased in the HF + 
10% MC group compared to the group fed a high fat diet alone. Phosphoinositide-
dependent kinase 1 is a serine/threonine protein kinase important in regulating insulin 
signaling through activation of Akt/protein kinase B (PKB) 
[19,23]
.  An increased 
expression of PDK-1 in these animals may suggest improved insulin signaling compared 
to mice fed a high fat diet. There were no significant differences between the groups in 
genes involved in fatty acid oxidation (Acox1), fatty acid synthesis (Acaca), 
gluconeogenesis (Fbp1 and G6pc), glycogenolysis (Gck), or hormones secreted from the 
adipose tissue (Lep & Retn). There was also no significant difference between groups in 
the gene that encodes for IRS-1, which is important as this is a major point of insulin 
signaling regulation or in the inflammatory kinase JNK pathway.  
 A second PCR array was completed to determine the effects of both bitter melon 
and TLR 4 on genes related to the toll-like receptor signaling pathways. Results indicated 
an increase in C3H/HeJ mice of genes related to the innate immune response (CD14, 
Hspd1, Csf3, Fos, Irak1, and Ly86) indicating an increase in the inflammatory response 
in C3H/HeJ compared to C57BL/6 mice when fed a high fat diet. Results also indicated 
an increase in Chuk, a gene which encodes for the IKK α, the inhibitor of NFκB possibly 
demonstrating a decreased activation of NFκB. However, there were no changes in TLR 
4 which would have been expected in C3H/HeJ mice since they only contain a mutation 
related to functionality of the receptor. Additionally, there were no significant differences 
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in the MyD88, an adapter protein for TLR 4, or downstream proteins of TLR 4 activation 
(JUN).  Additional results from this PCR array were more in line with expected 
outcomes. Wild-type mice (C57BL/6) fed the HF +10% MC diet had significantly lower 
TNF levels when compared with mice fed the high fat diet alone. These results 
implicated an anti-inflammatory effect of bitter melon.   
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Table 1. Composition of Bitter Melon Used in the Study* 
 
Analyte Amount (g/100g) 
Carbohydrate 75.3 
Protein 10.2 
Fat 2.69 
Crude Fiber 14.2 
Ash 8.91 
Calcium 0.231 
Phosphorus 0.603 
Calories (kcal/100g) 366 
* Analyzed by Nestle Purina Analytical Laboratories (St. Louis, MO). 
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Table 2. Diet Composition 
a
  
a All diets were prepared by Harlan Teklad Diets (Madison, WI) 
b Based on AIN-93M formulations, caloric contribution for carbohydrate, fat and protein is 72%, 4% and 
14%, respectively (Reeves et al., 1997) 
c All high fat diets have similar carbohydrate, fat, protein, calcium and phosphorus content. The caloric 
contribution for carbohydrate, fat and protein is 23.0%, 59.1%, and 17.9%, respectively.  
d Bitter melon composition was analyzed by Nestle Purina Analytical Laboratories (St. Louis, MO). Please 
see Table 1.  
 
 Control 
(AIN-93M)
b 
 
High Fat 
(HF)
c 
HF +1% 
Bitter Melon
c 
HF + 10% 
Bitter Melon
c 
Ingredients  (g/kg of diet) 
Freeze dried MC   10 100 
     
Total Carbohydrate
 
600.0 295.0 295.0 295.0 
Cornstarch
 
495.5 44.5 37.2  
Maltodextrin
 
40.0 160.0 160.0 131.6 
Sucrose
 
100.0 90.0 90.0 90.0 
Contribution of freeze dried 
MC
d 
  7.53 75.3 
     
Total Protein
 
210.0 265.0 265.0 265.0 
Casein
 
210.0 265.0 264.0 254.8 
Contribution of freeze dried 
MC
d 
  1.02 10.2 
     
Total Fat
 
40.0 340.0 340.0 340.0 
Soybean oil
 
40.0 30.0 29.7 27.3 
Lard
 
 310.0 310.0 310.0 
Contribution of freeze dried 
MC
d 
  0.269 2.69 
     
Total Fiber
 
50.0 50.0 50.0 50.0 
Cellulose
 
50.0 50.0 48.6 35.8 
Contribution of freeze dried 
MC
d 
  1.42 14.2 
     
Vitamin mix (AIN -93VX)
a 
10.0 10.0 10.0 10.0 
Mineral mix  
(AIN-93G-MX)
a 
35.0 35.0 35.0 35.0 
Choline Bitartrate  2.5 2.5 2.5 2.5 
L-cysteine 3.0 3.0 3.0 3.0 
Tert-butylhydroquinone 0.04 0.06 0.06 0.06 
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Table 3. Initial and final body weights and food intake 
 
Dietary 
Treatment 
Strain n Initial body 
weight (g) 
Final body 
weight (g) 
Food intake 
(kcal/mice/day) 
AIN C3H/HeJ 11 18.2 ± 0.4 29.5 ± 0.9 14.6 ± 0.3
c 
AIN C57BL/6 12 18.0 ± 0.4 27.1 ± 0.9 13.3 ± 0.3
d 
HF C3H/HeJ 12 18.4 ± 0.4 35.6 ± 0.9 15.7 ± 0.3
b 
HF C57BL/6 12 18.0 ± 0.4 34.9 ± 0.9  15.4 ± 0.3
bc 
HF+1% MC C3H/HeJ 12 18.0 ± 0.4 36.0 ± 0.9 16.0 ± 0.3
b 
HF+1% MC C57BL/6 12 18.0 ± 0.4 35.3 ± 0.9 17.0 ± 0.3
a 
HF+10% MC C3H/HeJ 12 18.4 ± 0.4 32.3 ± 0.9 16.0 ± 0.3
b 
HF+10% MC C57BL/6 13 18.0 ± 0.4 30.3 ± 0.8 15.5 ± 0.3
b 
      
Dietary Treatments 
AIN  23 18.1 ± 0.3 28.3 ± 0.6
C 
14.0 ± 0.2
C
 
HF  24 18.2 ± 0.3 35.3 ± 0.6
A 
15.6 ± 0.2
B 
HF+1% MC  24 18.0 ± 0.3 35.6 ± 0.6
A 
16.5 ± 0.2
A 
HF+10%MC  25 18.2 ± 0.3 31.3 ± 0.6
B 
15.8 ± 0.2
B 
Strain 
C3H/HeJ  47 18.3 ± 0.2 33.3 ± 0.4 15.6 ± 0.2 
C57BL/6  49 18.0 ± 0.2 31.9 ± 0.43 15.3 ± 0.2 
P values 
Diet   0.9472 < .0001 < .0001 
Strain   0.3993 0.0210 0.3300 
Diet*Strain   0.9316 0.6711 0.0005 
Values represent mean ± standard error of the mean. p < 0.05 is considered statistically significant. Values 
that do not share the same letter are considered statistically different. Lower case letters indicate significant 
differences related to a diet and strain interaction, capital letters indicate significant differences between 
dietary treatment group.  
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Table 4. Relative tissue weights (gram of tissue/gram body weight) 
 
Dietary 
Treatment 
Strain n Liver 
 (%) 
Peri-renal 
WAT (%) 
Visceral 
WAT (%) 
Spleen (%) Kidney (%) Thymus 
 (%) 
AIN C3H/HeJ 11 3.95 ± 0.10 0.63 ± 0.10
d 
2.19 ± 0.25 0.35 ± 0.07 1.83 ± 0.05 0.13 ± 0.01 
AIN C57BL/6 12 4.05 ± 0.10 0.72 ± 0.09
d 
2.06 ± 0.24 0.32 ± 0.07 1.35 ± 0.05 0.21 ± 0.01 
HF C3H/HeJ 12 3.50 ± 0.10 1.16 ± 0.09
bc 
4.59 ± 0.24 0.31 ± 0.07 1.56 ± 0.05 0.12 ± 0.01 
HF C57BL/6 12 3.64 ± 0.10 2.06 ± 0.09
a 
4.56 ± 0.24 0.27 ± 0.07 1.17 ± 0.05 0.21 ± 0.01 
HF+1% MC C3H/HeJ 12 3.41 ± 0.10 1.11 ± 0.09
c 
4.49 ± 0.24 0.27 ± 0.07 1.53 ± 0.05 0.11 ± 0.01 
HF+1% MC C57BL/6 12 3.52 ± 0.10 2.01 ± 0.09
a 
4.78 ± 0.24 0.25 ± 0.07 1.22 ± 0.05 0.19 ± 0.01 
HF+10% MC C3H/HeJ 12 3.49 ± 0.10 1.06 ± 0.09
c 
4.19 ± 0.24 0.51 ± 0.07 1.65 ± 0.05 0.08 ± 0.01 
HF+10% MC C57BL/6 13 3.55 ± 0.09 1.39 ± 0.09
b 
3.35 ± 0.23 0.27 ± 0.06 1.30 ± 0.05 0.20 ± 0.01 
Dietary Treatments    
AIN  23 4.00 ± 0.07
A 
0.67 ± 0.07
C
 2.13 ± 0.17
C 
0.34 ± 0.05  1.59 ± 0.04 0.17 ± 0.01
A 
HF  24 3.57 ± 0.07
B 
1.61 ± 0.07
A 
4.58 ± 0.17
A 
0.29 ± 0.05 1.36 ± 0.03 0.16 ± 0.01
AB 
HF+1% MC  24 3.47 ± 0.07
B 
1.56 ± 0.07
A
 4.63 ± 0.17
A 
0.26 ± 0.05 1.38 ± 0.03 0.15 ± 0.01
AB 
HF+10% MC  25 3.52 ± 0.07
B 
1.23 ± 0.06
B 
3.77 ± 0.17
B 
0.39 ± 0.05 1.48 ± 0.03 0.14 ± 0.01
B 
Strain    
C3H/HeJ  47 3.59 ± 0.05 0.99 ± 0.05 3.86 ± 0.12 0.36 ± 0.03 1.64 ± 0.02 0.11 ± 0.01 
C57BL/6  49 3.69 ± 0.05 1.55 ± 0.05 3.69 ± 0.12 0.28 ± 0.03 1.26 ± 0.02 0.20 ± 0.01 
P values    
Diet   < .0001 < .0001 < .0001 0.2487 < .0001 0.1298 
Strain   0.1361 < .0001 0.3106 0.0767 < .0001 < .0001 
Diet*Strain   0.9802 < .0001 0.1197 0.2518 0.2945 0.2949 
Values represent mean ± standard error of the mean. p < 0.05 is considered statistically significant. Values that do not share the same letter are 
considered statistically different. Lower case letters indicate significant differences related to a diet and strain interaction, capital letters indicate 
significant differences between dietary treatment groups. 
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Table 5. Body composition  
Dietary 
Treatment 
Strain n Lean Mass 
(g) 
Fat Mass 
(g) 
% Fat % Lean BMD 
(mg/cm
2
) 
BMC  
(mg) 
BMA  
(cm
2
) 
AIN C3H/HeJ 11 21.4 ± 0.5 7.90 ± 0.6 26.8 ± 1.0 73.2 ± 1.0 59.7 ± 0.6 655.9 ± 13.5 11.0 ± 0.2 
AIN C57BL/6 12 20.2 ± 0.4 6.68 ± 0.5 24.9 ± 0.9 75.1 ± 0.9 49.2 ± 0.6 497.2 ± 12.9 10.1 ± 0.2 
HF C3H/HeJ 12 22.9 ± 0.4 12.9 ± 0.5 35.9 ± 0.9 64.1 ± 0.9 58.1 ± 0.6 591.8 ± 12.9 10.2 ± 0.2 
HF C57BL/6 12 22.9 ± 0.4 12.1 ± 0.5 34.2 ± 0.9 65.8 ± 0.9 49.4 ± 0.6 462.8 ± 12.9 9.37 ± 0.2 
HF+1% MC C3H/HeJ 12 22.8 ± 0.4 13.5 ± 0.5 37.0 ± 0.9 63.0 ± 0.9 57.5 ± 0.6 573.8 ± 12.9 9.97 ± 0.2 
HF+1% MC C57BL/6 12 23.2 ± 0.4 12.4 ± 0.5 34.7 ± 0.9 65.3 ± 0.9 49.3 ± 0.6 461.2 ± 12.9   9.35 ± 0.2 
HF+10% MC C3H/HeJ 12 21.6 ± 0.4 10.7 ± 0.5 33.0 ± 0.9 67.0 ± 0.9 59.2 ± 0.6 618.0 ± 12.9 10.4 ± 0.2 
HF+10% MC C57BL/6 12 20.9 ± 0.4 8.83 ± 0.5 29.6 ± 0.9 70.4 ± 0.9 48.9 ± 0.6 470.8 ± 12.9 9.61 ± 0.2 
Dietary Treatments     
AIN  23 20.8 ± 0.3
B 
7.30 ± 0.4
C
  25.8 ± 0.7
C 
74.2 ± 0.7
A
 
 
54.4 ± 0.4  576.5 ± 9.3
A 
10.5 ± 0.1
A 
HF  24 22.9 ± 0.3
A 
12.5 ± 0.4
A 
35.0 ± 0.7
A 
65.0 ± 0.6
C 
53.7 ± 0.4 527.3 ± 9.1
BC 
9.77 ± 0.1
BC 
HF+1% MC  23 23.0 ± 0.3
A 
12.9 ± 0.4
A
  35.9 ± 0.7
A 
64.1 ± 0.6
C 
53.4 ± 0.4 517.5 ±9.1
C 
9.66 ± 0.1
C 
HF+10% MC  25 21.2 ± 0.3
B 
9.80 ± 0.4
B 
31.3 ± 0.7
B 
68.7 ± 0.7
B 
54.0 ± 0.4 544.4 ± 9.1
B 
10.0 ± 0.1
B 
Strain     
C3H/HeJ  47 22.2 ± 0.2 11.3 ± 0.3 33.2 ± 0.5 66.8 ± 0.5  58.6 ± 0.3  609.9 ± 6.5  10.4 ± 0.1 
C57BL/6  48 21.8 ± 0.2  10.0 ± 0.3 30.9 ± 0.5 69.2 ± 0.5  49.2 ± 0.3 473.0 ± 6.5 9.61 ± 0.1 
P values     
Diet   < .0001 < .0001 < .0001 < .0001 0.3588 0.0001 < .0001 
Strain   0.2017 0.0011 0.0005 0.0005 < .0001 < .0001 < .0001 
Diet*Strain   0.2535 0.7475 0.7924 0.7924 0.1469 0.3084 0.8708 
Values represent mean ± standard error of the mean. p < 0.05 is considered statistically significant. Values that do not share the same letter are 
considered statistically different. Lower case letters indicate significant differences related to a diet and strain interaction, capital letters indicate 
significant differences between dietary treatment groups. BMC = bone mineral content, BMD = bone mineral density, BMA = bone mineral 
area.  
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Table 6. Plasma lipid parameters  
 
Dietary 
Treatment 
Strain n Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dL) 
HDL  
(mg/dL) 
NEFA (mEq/L) 
AIN C3H/HeJ 11 138.7 ± 7.9 118.7 ± 8.2 68.0 ± 3.1 0.66 ± 0.04
bc 
AIN C57BL/6 12 108.3 ± 8.7 42.1 ± 9.1 63.6 ± 3.4 0.94 ± 0.04
a 
HF C3H/HeJ 12 199.7 ± 7.5 101.3 ± 7.9 90.3 ± 2.9 0.71 ± 0.04
bc 
HF C57BL/6 12 152.6 ± 7.5 44.4 ± 8.2 77.3 ± 2.9 0.74 ± 0.04
bc 
HF+1% MC C3H/HeJ 12 209.1 ± 7.9 109.2 ± 8.2 89.7 ± 3.1 0.70 ± 0.04
bc 
HF+1% MC C57BL/6 12 163.6 ± 7.5 40.6 ± 7.9 78.0 ± 2.9 0.71 ± 0.04
bc 
HF+10% MC C3H/HeJ 12 177.9 ± 7.9 73.7 ± 8.2 81.9 ± 3.1 0.65 ± 0.04
c 
HF+10% MC C57BL/6 13 137.0 ± 7.2 30.1 ± 7.6 71.6 ± 2.8 0.77 ± 0.04
b 
Dietary Treatments  
AIN  23 123.5 ± 5.9
C 
80.4 ± 6.1
A 
65.8 ± 2.3
C 
0.80 ± 0.03 
HF  24 176.1 ± 5.3
A 
72.8 ± 5.7
A 
83.8 ± 2.1
A 
0.73 ± 0.03 
HF+1% MC  24 186.3 ± 5.4
A 
74.9 ± 5.7
A 
83.8 ± 2.1
A 
0.71 ± 0.03 
HF+10% MC  25 157.5 ± 5.3
B 
51.9 ± 5.6
B 
76.8 ± 2.1
B 
0.71 ± 0.03 
Strain  
C3H/HeJ  47 181.3 ± 3.89 100.7 ± 4.07  82.5 ± 1.51 0.68 ± 0.02 
C57BL/6  49 140.4 ± 3.88 39.3 ± 4.11 72.6 ± 1.50 0.79 ± 0.02 
P values  
Diet   < .0001 0.0041 < .0001 0.1296 
Strain   < .0001 < .0001 < .0001 0.0003 
Diet*Strain   0.7268 0.2117 0.5340 0.0102 
Values represent mean ± standard error of the mean. p < 0.05 is considered statistically significant. Values that do not share the same letter are 
considered statistically different. Lower case letters indicate significant differences related to a diet and strain interaction, capital letters indicate 
significant differences between dietary treatment groups. HDL = high density lipoprotein, NEFA = non-esterified fatty acids. 
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Table 7. Clinical parameters related to glucose metabolism and insulin resistance 
Dietary 
Treatment 
Strain n Hemoglobin 
AIC (%) 
Glucose 
(mg/dL)
 
Fructosamine 
(µmol/L) 
Leptin 
(mg/mL) 
Adiponectin 
(mg/mL) 
Total AUC 
 (min*mg/dL) 
AIN C3H/HeJ 11 4.52 ± 0.2 164.2 ± 8.5
abc 
212.3 ± 13.7 2.77 ± 1.6 6.75 ± 0.6 31169.8 ±  1874.2
bc
 
AIN C57BL/6 12 4.63 ± 0.2 143.5 ± 8.5
cd 
241.3 ± 14.4 1.64 ± 1.6 11.0 ± 0.7 27320.4 ± 1874.2
c
 
HF C3H/HeJ 12 4.25 ± 0.2 153.3 ± 8.5
bcd 
233.2 ± 13.1 13.9 ± 1.5 7.44 ±0.7 32838.1 ± 1874.2
b
 
HF C57BL/6 12 4.72 ± 0.2 187.6 ± 8.5
a 
255.4 ± 13.1 16.2 ± 1.5 9.80 ± 0.6 42035.2 ± 1874.2
a
 
HF+1% MC C3H/HeJ 12 4.30 ± 0.2 161.2 ± 8.5
bcd 
217.0 ± 13.1 14.1 ± 1.5 6.85 ± 0.6 35404.2 ± 1874.2
b
 
HF+1% MC C57BL/6 12 4.73 ± 0.2 172.3 ± 8.5
ab 
255.7 ± 12.5 16.3 ± 1.5 11.9 ± 0.6 40659.4 ± 1874.2
a
 
HF+10% MC C3H/HeJ 12 4.25 ± 0.2 138.6 ± 8.5
d 
202.2 ± 13.1 6.26 ± 1.5 6.51 ± 0.6 30527.1 ± 1800.7
bc
 
HF+10% MC C57BL/6 13 4.78 ± 0.2 148.6 ± 8.2
cd 
271.4 ± 12.5 5.12 ± 1.6 9.98 ± 0.7 33893.3 ± 1874.2
b
 
Dietary Treatments    
AIN  23 4.57 ± 0.2 153.8 ± 6.0
AB
  226.8 ± 10.0 2.20 ± 1.1
C
  8.89 ± 0.5 29245.1 ± 1325.3
B
 
HF  24 4.48 ± 0.2 170.4 ± 6.0
A 
244.3 ± 9.2 15.1 ± 1.1
A 
8.62 ± 0.5 37436.7 ± 1325.3
A
 
HF+1% MC  24 4.52 ± 0.2 166.7 ± 6.0
A
  236.3 ± 9.0 15.2 ± 1.1
A 
9.39 ± 0.5 38031.8 ± 1325.3
A
 
HF+10% MC  25 4.52 ± 0.2 143.6 ± 5.9
B 
236.8 ± 9.0 5.69 ± 1.1
B 
8.24 ± 0.5 32210.2 ± 1299.5
B
 
Strain 
C3H/HeJ  47 4.33 ± 0.1 154.3 ± 4.3 216.2 ± 6.6 9.28 ± 0.8 6.89 ± 0.3 32484.8 ± 937.1 
C57BL/6  49 4.71 ± 0.1 163.0 ± 4.2 255.9 ± 6.6 9.82 ± 0.8 10.7 ± 0.3 35977.1 ± 928.0 
P values    
Diet   0.9835 0.0073 0.6484 < .0001 0.3417 < .0001 
Strain   < .0001 0.1495 < .0001 0.6281 < .0001 0.0096 
Diet*Strain   0.7778 0.0182 0.2867 0.5039 0.1831 0.0074 
Values represent mean ± standard error of the mean. p < 0.05 is considered statistically significant. Values that do not share the same letter are 
considered statistically different. Lower case letters indicate significant differences related to a diet and strain interaction effect, capital letters 
indicate significant differences between dietary treatment groups,  and * indicates significant differences between strains.
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Table 8. Effects of Bitter Melon and TLR 4 on Liver Steatosis  
 
 
Diet Steatosis Frequency Chi-Square 
 0 1 2 3 4 
0.0173 
Control 6 2 1 3 0 
HF 1 2 4 2 0 
HF + 1% MC 1 1 5 3 0 
HF + 10% MC 10 1 1 0 0 
Strain   
 0 1 2 3 4 
0.8949 C3H/HeJ 8 3 6 3 0 
C57BL/6 10 3 5 5 0 
 
Steatosis was graded on a 0-4 basis depending on how many hepatocytes were involved and the degree of 
severity in these cells, 0 indicates no steatosis and 4 indicates severe steatosis. A Chi-Square value < 0.05 is 
considered statistically significant.  
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Table 9. Relative mRNA expression of genes related to PPAR signaling in the liver of C57BL/6 mice 
 
Gene Name Gene Symbol 
Control: 
AIN-93M 
HF +  
1% MC 
HF +  
10% MC 
Avg. CT 
Acetyl-Coenzyme A carboxylase alpha Acaca -30.1 -1.14 +2.93 22.2 
Acyl-Coenzyme A oxidase 1, palmitoyl Acox1 +1.48 -1.15 +2.94 21.5 
Bcl2-like 1 Bcl2l1 +2.65 +5.05 +21.3* 31.9 
Fructose bisphosphatase 1 Fbp1 +2.06 -1.38 +2.78 27.9 
Glucose-6-phosphatase, catalytic G6pc +1.42 +1.05 +3.14 25.4 
Glucokinase Gck +1.21 -2.89 +1.63 28.5 
Insulin receptor substrate 1 Irs1 +1.90 -1.08 -1.61 24.8 
Jun oncogene Jun +1.16 -1.21 +2.48 17.7 
Leptin Lep -4.11 -4.38 -2.78 25.0 
Low density lipoprotein receptor Ldlr +1.38 -1.23 +3.02 24.6 
Phosphoenolpyruvate carboxykinase 2 
(mitochondrial) 
Pck2 +9.35 -1.08 +4.03 29.3 
3-phosphoinositide dependent protein kinase 
1 
PdPk1 +1.68 -3.13 +2.96* 27.3 
Resistin Retn +1.24 -1.10 +2.57 26.1 
Ribosomal protein S6 kinase polypeptide 1 Rps6ka1 -11.1* -1.83 -2.77 17.2 
Uncoupling protein 1 (mitochondrial, proton 
carrier) 
Ucp1 +1.50 +1.02 +1.95 22.8 
Values represent fold regulation which is determined using relative fold change. * indicates a significant fold regulation compared to the high 
fat diet group; p < 0.05 is considered statistically significant. 
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Table 10. Relative mRNA expression of genes related to toll-like receptor signaling in adipose tissue of C57BL/6 and 
C3H/HeJ mice receiving a high fat (HF) and 10% bitter melon (HF+10% MC) diet 
Gene Name Gene Symbol HF + 10% MC 
C57BL/6 
HF  C3H/HeJ HF + 10% MC 
C3H/HeJ 
Avg. CT 
CD14 antigen Cd14 +1.11 +20.8* +5.98 23.8 
Conserved helix-loop-helix 
ubiquitous kinase 
Chuk +1.17 +15.6* +6.67 
25.1 
Colony stimulating factor 3 
(granulocyte) 
Csf3 +8.08 +29.5* +2.21 
31.1 
FBJ osteosarcoma oncogene Fos -1.36 +19.2* +6.97 22.5 
Heat shock protein 1 (chaperonin) Hspd1 +1.32 +7.83* +2.83 21.4 
Interleukin 6 Il6 -1.70 +5.97 +1.38 29.3 
Interleukin-1 receptor-associated 
kinase 1 
Irak1 +1.36 +5.74* +2.39 
23.0 
Jun oncogene Jun +1.37 +4.51 -21.2 23.5 
Lymphocyte antigen 86 Ly86 -1.15 +103.3* +27.9 25.6 
Myeloid differentiation primary 
response gene 88 
Myd88 -1.52 +3.94 -2.35 
26.0 
Toll-like receptor 4 Tlr4 +1.13 +3.70 +1.37 22.7 
Tumor necrosis factor Tnf -2.11* +3.47 +1.07 27.0 
Values represent fold regulation which is determined using relative fold change. * indicates a significant fold regulation compared to C57BL/6 
mice fed a high fat diet; p < 0.05 is considered statistically significant.   
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Figure 1. Weekly body weights; dashed line represents C57Bl/6 mice; solid line represents 
C3H/HeJ mice. * indicate significant differences between dietary treatment groups. ** indicates 
significant difference seen between strains. 
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Figure 2. Results of a glucose tolerance test. * indicate significant differences between dietary 
treatment groups. ** indicates significant difference seen between strains. *** indicates 
significant diet and strain interaction.                                                                                                                           
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CHAPTER V 
 
 
DISCUSSION 
 The purpose of this study was two-fold:  (1) to determine whether freeze-dried 
bitter melon powder supplementation, in 1 and 10% doses, could prevent the 
development of high fat diet induced obesity and insulin resistance, which further 
contributes to dyslipidemia and alterations in body composition, and (2) to determine the 
role of TLR 4 in the development of obesity-associated inflammation and insulin 
resistance and whether the deletion of TLR 4 would play a protective role. To address the 
objectives of this study, two strains of mice were used, C57BL/6 and C3H/HeJ, mice 
with a loss of function mutation of TLR 4.  
 Differences in strains were apparent from the results of this study. Mice with a 
deficiency in TLR 4 (C3H/HeJ) exhibited an increased body weight and body fat 
percentage compared to the C57BL/6 mice; however, the caloric intake did not differ 
between strains, so this could not be deemed as the primary cause in the observed 
differences in body fat. Our findings were similar to that of Poggi and colleagues, in 
which C3H/HeJ mice exhibited elevated body weights compared to wild-type mice when 
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fed a high fat diet 
[4]
. They contributed the weight gain to increases in body fat mass and 
hypothesized that TLR 4 may play a role in regulating the balance between energy intake 
and expenditure 
[4]
.  
Surprisingly, C3H/HeJ mice also had significantly elevated blood lipid levels, 
including total cholesterol and plasma triglycerides. However, their NEFA levels, a 
known ligand for TLR 4 activation, were significantly lower compared to C57BL/6 mice. 
Adiponectin, an adipokine with an anti-diabetic effect, was also significantly lower in 
C3H/HeJ mice. Our findings are different from what has been reported by Sugananami 
and colleagues 
[62]
. Their results showed that C3H/HeJ mice had a higher serum 
adiponectin level as well as an increased adiponectin mRNA expression in epididymal 
WAT, indicating a possible role of adiponectin in improving insulin resistance 
[62]
. 
However, our results do not support this hypothesis and we cannot offer an explanation at 
this time.  
 Even with significantly elevated % body fat and blood lipids, and lower 
adiponectin levels, C3H/HeJ mice exhibited an improved glucose tolerance compared to 
C57BL/6 mice. A lower total area under the curve after a glucose tolerance test indicated 
improved glucose control in C3H/HeJ mice compared to wild-type mice.  Additionally, 
C3H/HeJ mice had lower fructosamine and hemoglobin A1C levels. Blood lipid levels, 
lower adiponectin levels and increased body fat would generally be associated with 
insulin resistance, however in this study C3H/HeJ mice did not appear to be insulin 
resistant. We therefore speculated that other factors, rather than body fat, blood lipids, 
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and reduced adiponectin may be an important contributing factor to glucose intolerance 
and insulin resistance in this strain of mice.  
To assess the possible role of inflammation as a contributing factor to glucose 
intolerance and insulin resistance, plasma TNF-α levels were assayed as a marker of 
inflammation. However, the assay kit that was used was not sensitive enough and 
additional inflammatory markers could not be assayed due to limited amounts of plasma 
samples. However, C3H/HeJ mice had significantly lower NEFA concentrations, which 
have been shown to contribute to inflammation and insulin resistance 
[28]
. Tsukumo and 
colleagues attributed the protection from glucose intolerance in C3H/HeJ mice to be due 
to the attenuated levels not just of the inflammatory cytokines, TNF-α and IL-6, but also 
to circulating NEFA 
[63]
. We speculate that the positive effect of TLR 4 deficiency on 
glucose tolerance observed in our study is also due to attenuated levels of a combination 
of NEFA and pro-inflammatory markers. Future studies should assess these pro-
inflammatory markers.  
 C3H/HeJ mice exhibited increased expression of several genes related to the 
innate immune response. Several proteins required for toll-like receptor signaling were 
up- regulated in C3H/HeJ mice including interleukin-1 receptor-associated kinase 
(IRAK) and CD14,  a serine/threonine kinase which is involved in toll-like receptor 
signaling and an adapter protein required for TLR 4 signaling, respectively 
[96,97]
. Other 
genes related to inflammation such as Csf3, which encodes proteins that function as 
granulocytes, as well as Hspd1, related to the functioning of heat shock proteins, were 
elevated in C3H/HeJ mice when compared to C57Bl/6 mice when both were fed a high 
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fat diet 
[96,97]
. The role of these proteins in regulating inflammation indicates an increase 
in inflammation in C3H/HeJ mice compared to C57BL/6 mice. These results contradict 
our speculation that inflammation played a significant role in the development of insulin 
resistance in C3H/HeJ mice. Further research is needed to determine the mechanism 
through which glucose intolerance and insulin resistance develops in the absence of TLR 
4.  
Based on the previously reported phenotype of C3H/HeJ mice and the improved 
glucose tolerance observed in this study, the increased expression of inflammatory genes 
was not expected. However, the small sample size used in this array (n=3/group) might 
have contributed to this discrepancy. Also, our results showed an increased body fat 
percentage as well as an increased body weight which is also not normally seen in 
C3H/HeJ mice. These results may have contributed to the increase in inflammation in the 
C3H/HeJ mice. A high fat diet with 60% of calories from fat was used in this study, 
while previous studies have utilized either a 45 or 55% high fat diet 
[4, 68]
. This difference 
in dietary treatment may have also contributed to the results observed in this study.  
 The other objective of this study was to determine the effects of bitter melon, in 
1% and 10% doses, on the development of high fat diet induced obesity, inflammation 
and insulin resistance. We found that bitter melon, in a 10% dose, played a protective role 
in the development of insulin resistance and attenuated weight gain, specifically body fat 
accumulation. Mice fed a HF + 10% MC diet, had significantly lower body weights 
compared to the other high fat diet groups. While the caloric intake of the HF +10% MC 
group was lower compared to the HF + 1% MC group, it was similar to mice fed a high 
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fat diet alone, indicating caloric intake was likely not a major factor in modulating weight 
gain. We also observed that mice on the HF + 10% MC diet had significantly lower 
relative peri-renal and visceral fat pad weights, as well as body fat percentage and total 
fat mass compared to the other high fat groups. Associated with body fat percentages, 
leptin levels were significantly lower in mice supplemented with 10% MC compared to 
other high fat groups, however no differences in adiponectin were observed. Bitter 
melon’s effect in controlling weight gain, particularly the 10% dose, was likely due to its 
regulation of body fat accumulation. Previous research by Chen and colleagues showed 
the ability of MC, in only a 1.5% dose, to attenuate visceral adiposity in rats fed a high 
fat diet
 [87]
.  They attributed that bitter melon prevented the accumulation of body fat in 
rats through up regulation of thermogenesis and an increase in expression of genes 
typically found in brown adipose tissue, suggesting an increase in energy expenditure 
[87]
. 
They contributed to the lower amount of visceral adiposity to the reduced insulin in these 
animals which may have led to an increase in lipolysis. We have not investigated the 
mechanism of action of MC in attenuating weight gain and whether up-regulation of 
thermogenesis and energy expenditure occurred in our mice is not known at this time. 
Future research is needed to determine the role of bitter melon in thermogenesis and 
energy expenditure.  
In line with previous research, bitter melon was able to prevent dyslipidemia 
associated with consumption of a high fat diet 
[85,86]
. Total cholesterol and triglycerides 
were significantly lower in the HF + 10% MC group compared to other high fat diet 
groups. Similar results were shown by Senanayake and colleagues where the methanol 
extract of MC was effective in lowering hepatic and serum triglyceride levels in Sprague-
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Dawley rats 
[86]
. Another study by the same research group indicated the ability of MC to 
improve cholesterol levels in a dose dependent manner 
[85]
. Senanayake and colleagues 
attributed the ability of bitter melon to attenuate serum lipids by modulating the synthesis 
of triglycerides in the liver 
[85]
.   
 The hypoglycemic effect of bitter melon has been extensively investigated and 
documented in animal models 
[82-84]
. In the present study, bitter melon in a 10% dose, was 
able to normalize the glucose intolerance that is commonly induced with a high fat diet. 
Fasting glucose levels of mice supplemented with 10% MC were equivalent to levels 
observed in mice fed the control diet. Similarly, results of a glucose tolerance test 
following 8 weeks of feeding, showed an improved glucose tolerance in mice fed the HF 
+ 10% MC diet. Interestingly, bitter melon had a stronger effect on C3H/HeJ mice 
compared to the wild-type mice. In an attempt to understand the hypoglycemic action of 
bitter melon, a gene expression analysis was performed. We have observed that bitter 
melon was able to increase PdPk1 and RPS6Ka1,  indicating improved insulin signaling. 
Other investigators have reported several mechanisms by which bitter melon, or its active 
components such as polypeptide-p, vicine or charantin, modulate glucose homeostasis. 
These mechanisms include the activation of the AMPK pathway which acts to increase 
GLUT 4 translocation to the cell membrane 
[91]
. In vitro and in vivo studies have shown 
that MC extracts were able to increase uptake of glucose in skeletal muscle and adipose 
tissue 
[98-100]
. MC has also been shown to increase hepatic glucose utilization and 
glycogen synthesis as well as decrease hepatic gluconeogenesis 
[101-102]
.  
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  Bitter melon, in a 10% dosage, was also able to attenuate liver gene expression of 
TNF-α compared to mice fed a high fat diet alone in wild-type mice. This suggests a role 
of bitter melon in attenuating inflammation. Gadang and colleagues showed that bitter 
melon seed (3% w/w) was able to down-regulate the expression of NFκB and increase the 
expression of PPARγ in Zucker rats [84]. Bitter melon’s ability to attenuate inflammation 
may also explain the positive effect of MC on glucose tolerance. Other research has 
indicated bitter melon may act to regulate the PPARγ mediated pathway to prevent 
inflammation and insulin resistance 
[87,88]
. Further research is required to solidify the 
mechanism of action of bitter melon.  
The results of our study provided evidence to reject three of our four null 
hypotheses:   
1. Bitter melon added to a high fat diet will not improve the plasma lipid profile in 
both strains of mice. Our results have shown that bitter melon, in a 10% dose, was 
able to attenuate total cholesterol and triglycerides. However, bitter melon had 
different effects on NEFA levels in C3H/HeJ and C57BL/6 mice. C3H/HeJ mice 
fed the HF + 10% MC diet had significantly lower NEFA levels compared to 
C57BL/6 mice fed the same diet.  
2. Bitter melon will not affect glucose homeostasis in both strains of mice. In our 
study, 10% bitter melon was able to significantly improve the glucose tolerance of 
both strains of mice; however, it was more effective in C3H/HeJ mice. The total 
AUC in C3H/HeJ mice fed the HF + 10% MC diet was similar to mice fed the 
control diet.  
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3. Bitter melon will not affect body composition in both strains of mice. Bitter melon 
in a 10% dose was able to prevent accumulation of fat mass induced by a high fat 
diet, this was similar in both strains of mice. The body fat percentage of the HF + 
10% MC group was significantly lower compared to mice fed a high fat diet 
alone.  
However, we were not able to reject our null hypothesis that: Biomarkers of 
inflammation will not be lower in mice fed bitter melon compared to mice consuming 
a high fat diet in both strains of mice. Our PCR results have shown that gene 
expression of TNF was significantly lower in C57BL/6 mice fed a HF + 10% MC diet 
but the same effect was not observed in C3H/HeJ mice. As stated previously, 
additional research is needed to determine other markers of inflammation that may 
have been affected by our dietary treatment. 
 Future research is needed to determine the hypoglycemic, hypolipidemic, and 
body composition modulating mechanism of action of bitter melon. Additionally, 
studies in humans are necessary to see if these positive effects will be observed. 
However, the dose suitable for human consumption as well as safety needs to be 
examined. Another limitation of our study was the inability to quantify the 
inflammation present in our animals. We are currently assessing adipose tissue 
histology and degree of inflammation. Due to limited plasma samples, we were not 
able to assess plasma pro-inflammatory markers as well as insulin. This would have 
been helpful to determine the insulin/glucose ratio which would have helped us 
determine the action of bitter melon in regards to its role in insulin resistance.  
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